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1 ABSTRACT 
 
The innate immune system protects cells against invading viral pathogens by 
the auto- and paracrine action of type I interferon (IFN). In addition, the 
interferon regulatory factor (IRF)-1 can induce alternative intrinsic antiviral 
responses. Although both, type I IFN and IRF-1 mediate their antiviral action by 
inducing overlapping subsets of IFN stimulated genes, the functional role of this 
alternative antiviral action of IRF-1 in context of viral infections in vivo remains 
unknown. Here, we report that IRF-1 is essential to counteract the 
neuropathology of vesicular stomatitis virus (VSV). IFN- and IRF-1-dependent 
antiviral responses act sequentially to create a layered antiviral protection 
program against VSV infections. Upon intranasal infection, VSV is cleared in the 
presence or absence of IRF-1 in peripheral organs, but IRF-1-/- mice continue to 
propagate the virus in the brain and succumb. Although rapid IFN induction 
leads to a decline in VSV titres early on, viral replication is re-enforced in the 
brains of IRF-1-/- mice. While IFN provides short-term protection, IRF-1 is 
induced with delayed kinetics and controls viral replication at later stages of 
infection. IRF-1 has no influence on viral entry but inhibits viral replication in 
neurons and viral spread through the CNS, which leads to fatal inflammatory 
responses in the CNS. These data support a temporal, non-redundant antiviral 
function of type I IFN and IRF-1, the latter playing a crucial role in late time 
points of VSV infection in the brain. 
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2 INTRODUCTION 
2.1 Viral detection and signaling 
Recognition of invading pathogens is central to the host immune system. The 
innate immune system which is considered the first line of defences depends on 
a limited number of germline encoded receptors called pathogen recognition 
receptors (PRRs) to recognize pathogen-associated molecular patterns 
(PAMPs). Two families of PRRs that recognize viral nucleic acid have been 
characterized in detail (listed in Table 1). The first is a subfamily of Toll-like 
receptors (TLRs) that is made up of TLR1, TLR2, TLR3, TLR7, TLR8 and TLR9, 
which are mainly expressed in the endosomes of some cell types. The second 
family of receptors comprises the retinoic-acid-inducible gene I (RIG-I)-like 
receptors (RLRs), encompassing RIG-I, melanoma differentiation-associated 
gene 5 (MDA5). 
Depending on the nature of the pathogen and cell type involved, signal 
transduction pathways are activated by PAMP-engaged PRRs so as to elicit 
antimicrobial responses by inducing various target genes that include those 
encoding type I IFNs, proinﬂammatory cytokines, and chemokines. Three major 
signalling pathways responsible for mediating PRR responses include (i) NF-κB, 
(ii) mitogen-activated protein kinases (MAPKs), and (iii) IFN regulatory factors 
(IRFs). While NF-κB and MAPKs play central roles in induction of a 
proinflammatory response, IRFs are essential for stimulation of IFN production. 
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Table 1: Viral PAMPs 
PRR Viral PAMP Virus (reference) 
TLR3 Endosomal dsRNA RNA viruses [1,2] such as 
 Reovirus [3] 
 MCMV [4] 
 Rhinovirus [5] 
 West Nile virus [6] 
 Influenza A [7] 
TLR7 ssRNA  Influenza A [8-10] 
 VSV [10] 
TLR8 ssRNA  HIV [8] 
TLR9 Unmethylated DNA  HSV-1/2 [11-13] 
 MCMV [14] 
RIG-I Cytoplasmic 5’-triphosphate 
dsRNA 
 Flaviviruses [15,16] 
 Paramyxovirus such as 
RSV-1 [15,17] 
 Orthomyxovirus, for 
example, influenza A 
virus [15] and EBV [18] 
MDA5 Cytoplasmic dsRNA  Picornaviruses [15,19] 
such as EMCV 
 
 
2.2 The IFN action 
Interferons (IFNs) are a group of secreted cytokines that are known to elicit 
distinct antiviral effects. Discovered in 1957 by Lindenmann and Isaacs for their 
antiviral properties [20], the type I IFNs are now grouped into three classes 
called type I, II and III IFNs, according to their amino acid sequence. Type I 
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IFNs comprise a large group of molecules; mammals have multiple distinct IFN-
α genes (13 in man), one to three IFN-β genes (one in man) and other genes, 
such as IFN-ω, -ϵ, -τ, -δ and -κ. IFN-α and –β genes are induced directly in 
response to viral infection, whereas IFN-ω, -ϵ, -δ and -κ play less well-defined 
roles, such as regulators of maternal recognition in pregnancy [21,22]. In this 
study we use the term type I IFNs to refer to IFN-α/β which are the virally 
induced cytokines. The rapid production of the type I IFN in response to a viral 
attack serves as a crucial antiviral defence mechanism in mammals [23-25]. The 
type I IFN response to invading pathogens is a biphasic phenomenon. First, the 
detection of viral PAMPs by various PRRs initiates a signalling cascade to 
activate transcription factors- interferon regulatory factor (IRF)-3 and NF-kB to 
induce the type I IFNs [26-28]. Second, the IFNs act in an autocrine and 
paracrine manner to induce interferon stimulated genes (ISGs), the products of 
which act collectively to interfere with viral replication and spread.  
Type II IFN has a single member, also called IFN-γ, and is secreted by activated 
T cells and natural killer (NK) cells, rather than in direct response to viral 
infection. 
Type III IFN also known as IFN-λ or IL-28 displays IFN-like activities [29,30] by 
exerting its action through a receptor complex distinct from the type I IFNs 
[31,32] 
IFNs mediate their responses by signalling through distinct but related pathways 
via specific type 1 or 2 receptors that bind to Janus kinases (JAKs) and 
subsequently activate signal transducers and activators of transcription 
(STATs), resulting in expression of a broad range of ISGs. IFN effectors vary 
widely in their magnitude of inhibitory activity and display combinatorial antiviral 
properties. Collectively, antiviral ISGs can target almost any step in a virus life 
cycle. To cite a few examples of those ISGs whose antiviral mechanisms are 
known, Rsad2 (viperin) prevents influenza A virus egress by perturbing lipid 
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rafts and promoting TLR7/9 signalling, OAS1/2/3 targets viral replication in 
flaviviruses by activating RNase L to degrade viral genome, and TRIM25 
activate RIG-I signalling to counter viruses such as VSV and influenza A virus. 
Microarray data and knockout studies have suggested that IFN-induced 
effectors form a diverse and overlapping landscape. Mice defective in one or 
more of the classical antiviral pathways (MX1, OAS, and PKR) still mount 
antiviral responses, indicating that several factors contribute to protection. This 
redundancy likely reflects the central importance of ISGs in antiviral defence. 
  
2.3 The IRF family functions 
Host defences in responses to a viral attack are achieved by the efficient 
coordination of cellular processes by genetic regulatory networks which ensure 
rapid alterations in gene-expression programs. The IFN-regulatory factor (IRF) 
family of transcription factors have been shown to have markedly diverse roles 
in the gene-regulatory networks of the immune system. The mammalian IRF 
family comprises nine members: IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-
7, IRF-8 and IRF-9 [33-35]. A brief summary of the roles of each transcription 
factor in antiviral signalling and responses can referred from Table 2.   
2.3.1 Roles in signaling 
IRFs play important roles in the establishment of signalling pathways that lead 
to innate immunity. For example- IRF-3 and IRF-7 are early IRFs activated by 
PRR signalling that play a pivotal role in the initial induction of type I IFNs. Upon 
activation, IRF-3 and IRF-7 are phosphorylated through the IκB kinase (IKK) 
family of kinases, dimerised, and translocated into the nucleus to stimulate IFN-
β and IFN-α transcription. Following IFN-receptor interaction, a latent 
cytoplasmic IRF-9 complexes with Stat1 and Stat2 through the activation of the 
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JAK/STAT pathway, binds to the IFN-stimulated response element (ISRE), and 
stimulates transcription of a large set of IFN-stimulated genes 
Each IRF contains a well-conserved DNA-binding domain of ∼120 amino acids 
which recognises a consensus DNA sequence that is known as the IFN-
stimulated response element (ISRE) which can be found on the promoters of 
ISGs. Thus IRFs also play key roles in the induction of overlapping sets of 
genes. 
2.3.2 Cellular antiviral responses  
IRF-1 was the first member to be discovered in the IRF family and the IRF-1 
transcription factor was originally identiﬁed as a regulator of virus inducible 
enhancer-like elements of the human IFN-β gene [36]. The consensus IRF-1 
binding sequence motif, now termed IRF-E, has been determined to  be  5’-
G(A)AAAG/CT/CGAAAG/CT/C-3’ [37]. Interestingly, sequences related to the 
consensus IRF-E motif appear within several IFN-stimulated genes (ISG), and 
for some of these genes, it was shown that IRF-1 directly binds to their 
promoters and activates transcription. IRF-1 mRNA levels have shown to 
accumulate in response to IFN, double-stranded RNA (dsRNA), cytokines, and 
some hormones. IFN-ɣ is the strongest IRF-1 inducer known, although certain 
combinations, such as IFN-ɣ and tumour necrosis factor-α (TNF-α) induce even 
higher levels of IRF-1 mRNA[38].   
IRF-1 regulates the expression of a number of genes and plays central roles in 
both innate and adaptive immunity. IRF-1 induces the transcription of many 
genes involved in the first reaction to viral invasion, such as PKR, OAS, viperin 
and iNOS [39-42]. IRF-1 also regulates adaptive immune responses by 
regulation of MHC class I expression and influencing development of NK and T 
cells [43,44]. Moreover, IRF-1-/- mice have shown influence Th1 responses.
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Table 2: A summary of IRF family member functions. 
IRFs Expression Role in immune and host defences 
IRF-1 Constitutive and IFN inducible 
 Stimulates expression of ISGs 
[41,42,45]. 
 Promotes Th1 responses [46]. 
 Required for differentiation of CD8+ 
T cells [47,48]. 
 Required for NK cell development 
[44]. 
 
IRF-2 Constitutive and IFN inducible 
 Antagonizes IRF-1 [49]. 
 Regulates Th1-Th2 balance [50].  
IRF-3 
 Constitutive in the cytoplasm 
 Phosphorylated upon viral infection 
and then translocated into the 
nucleus  
 Induces Type I IFNs, 
proinflammatory cytokines and 
chemokines [51-54]. 
 Stimulates expression of ISGs 
[55,56]. 
IRF-4 
 Constitutive in B cells, 
macrophages. 
 Inducible by antigen stimulation in 
T cells and by TLR signalling in 
macrophages. 
 Binds to MyD88 and negatively 
regulates TLR-dependent induction 
of proinﬂammatory cytokine genes 
[57,58]. 
 Promotes Th2 differentiation 
[59,60]. 
IRF-5 
 Constitutive in B cells and DCs. 
 Inducible by type I IFNs and TLR 
signalling. 
 Phosphorylated upon viral 
infection and then translocated 
into the nucleus 
 Binds to MyD88 and positively 
regulates TLR-dependent induction 
of proinﬂammatory cytokine genes 
(IL-12p40, IL-6, and TNF-α) [61]. 
 Induces type I IFNs and 
proinﬂammatory cytokines upon 
virus infection (type I IFNs, IL-6, 
and TNF-α) [61-63]. 
IRF-6 Constitutive in skin 
Required for keratinocyte differentiation 
[64,65] 
IRF-7 
 Constitutive in B cells, pDCs, and 
monocytes and inducible by type I. 
 Phosphorylated upon viral 
infection and then translocated 
into the nucleus. 
 Positively regulates the induction of 
the type I IFNs [66,67] 
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IRF-8 
 Expressed in macrophages, B 
cells and DCs and inducible by 
IFNs   
 Required for TLR9 signalling in 
DCs and macrophages [68]. 
 Promotes type I IFN production in 
DCs [69]. 
 Stimulates IFN-γ- and PAMP-
inducible genes [68]. 
IRF-9 
Constitutive and inducible by IFN-γ in 
various cell types 
Binds to STAT1 and STAT2 to form ISGF3 
and stimulates type I 
IFN–inducible genes [70,71] 
 
 
2.4 Viral evasion strategies 
The type I interferon (IFN) system mediates a wide variety of antiviral 
mechanisms and represents a crucial ﬁrst barrier to virus infection. However, to 
generate a productive infection, viruses must overcome antiviral responses, and 
accordingly, every aspect of these defences is targeted for inhibition. Viruses 
have thereby developed an impressive diversity of mechanisms to evade the 
IFN responses.  
Several viruses have been found to prevent initial detection by either interfering 
with the TLR or RLR signalling adaptor proteins such as TRIF or MAVS [72-74]. 
For example, 3CD protease-polymerase, an intermediate in the polyprotein 
processing cascade of hepatitis A virus [72] and 3C protein of enterovirus [73] 
use protease activity to cleave TRIF. The NS3/4A protease of hepatitis C virus, 
cleaves MAVS off the mitochondria to evade innate immunity [75]. Some viruses 
can overcome the host responses by manipulating PRR expression levels [76-
78] or by even concealing their genetic material to avoid detection [79,80]. In 
addition, the viruses express proteins that inhibit IFN action on different levels 
[81-83].  
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2.5 IRFs driving IFN independent innate immune responses 
Host cells have developed strategies to overcome viral evasion mechanisms by 
adding alternative mechanisms that are not simultaneously declined by the 
virus. Recent studies have implicated several IFN-independent antiviral 
mechanisms which bypass viral inhibition of IFN induction and function. Several 
IRFs have been shown to drive antiviral defence mechanisms independent of 
the type I IFN signalling in vitro. IRF-3 has been shown to induce a subset of 
ISGs by direct binding to their promoters before IFN itself can be produced 
[55,84]. In addition, IRF-1 dependent but IFN-independent inductions of antiviral 
effector functions against different viruses have been shown [42,85]. While 
mitochondrial MAVS are shown to carry out IFN dependent antiviral 
mechanisms, peroxisomal MAVS have been shown to induce an immediate 
albeit transient induction of anti-viral defence factors by IFN independent 
mechanisms [86]. Further proof of concept included a study which showed IRF-
1 mediated induction of several ISGs in STAT1-/- cells [87]. IRF-1 and IRF-5 has 
also shown to mediate antiviral responses against the hepatitis C virus by an 
IFN independent mechanism [88]. In addition to the IRF mediated antiviral 
mechanisms, some ISGs can be directly induced by viral infection in the 
absence of IFN production [89].  
2.6 Immunity in the Central Nervous System (CNS) 
The central nervous system (CNS) harbours highly differentiated cells, such as 
neurons that are essential to coordinate the functions of complex organisms. 
Numerous cell types act in accord to maintain its integrity and function. The cell 
types are separated into three main groups: neurons, the glia, and endothelial 
cells.  This organ is partly protected by the blood-brain barrier (BBB) from toxic 
substances and pathogens carried in the bloodstream. The BBB mechanically 
separates the CNS from the circulation by the presence of specialised 
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endothelial cells tightly attached to each other via tight junctions (TJs) and 
adherens junctions (AJs) [90,91]. The role for these junctions is to restrict and 
prevent blood-borne molecules and peripheral cells from entering the CNS. Yet, 
neurotropic viruses can reach the CNS either by infecting epithelial cells on the 
nasal route leading up to the brain [92], crossing the BBB after viremia [93], by 
exploiting motile infected cells as Trojan horses [94], or by using axonal 
transport [95]. For decades, the immune privilege of the CNS was understood 
as an absence of an immune system inside the CNS, and the BBB was 
considered only as a barrier isolating the CNS from the peripheral immune 
system, preventing the entry of infectious agents and immune cells into the CNS 
[96]. Extensive work in the last decade unravelled the presence of a specialised 
intrinsic innate immune system in the CNS. 
In the case of a viral infection in the brain, pattern recognition receptors (PRRs) 
recognise pathogen associated molecular patterns (PAMPs) and trigger the 
onset of antiviral defence mechanisms. The expression of PRRs such as TLRs, 
RLRs and NLRs have mostly been studied on glia, however, more recent 
studies have shown neurons to also harbour PRRs [97]. The engagement of 
such receptors results in the induction of speciﬁc pathways and the release of 
cytokines that play a role in antiviral defences. The engagement of viral PAMPs 
on TLRs and RLRs are known to drive IFN-β mediated antiviral responses while 
NLRs are known to drive antiviral responses mediated by IL-1β. 
Devoid of a lymphatic system, the integrity of the CNS is guarded exclusively 
through an innate immune system with an adaptive immunity only present in 
specific conditions. Classic APCs are normally not found in the CNS [98,99]. 
Microglia are the resident macrophage like population in the CNS and although 
they can perform effector inflammatory and APC functions, recent studies report 
that they originate from the yolk sac unlike hematopoietic cells [100]. Activated T 
cells are able to infiltrate the CNS, however if the CNS is non-inflamed  or if they 
do not there find a suitable antigen , they leave the CNS again or die by 
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apoptosis [101]. It is not entirely clear if B- cells can infiltrate to the CNS. 
Inflammatory responses in the CNS also lead to infiltration of monocytes such 
as neutrophils, macrophages and dendritic cells. 
2.7 Vesicular Stomatitis Virus (VSV) 
Many viruses are neurotropic i.e. they are capable of preferentially infecting 
brain cells. To name a few, west nile virus (WNV), tick borne encephalitis virus 
(TBEV), measles virus and rabies virus infections can cause severe encephalitic 
responses in humans that can lead to death. VSV belongs to the family 
Rhabdoviridae, to which the well-known rabies virus also belongs. Transmission 
of VSV to humans has been  documented only once due to laboratory 
contamination and the experimenter developed flu-like symptoms [102]. It is a 
common laboratory virus and its replication mechanism is well understood in 
several cell culture systems. Therefore, it has for decades been used as a 
model for neurotropic virus infections in mice [103]. VSV is an enveloped single 
stranded negatively sensed rod shaped RNA virus coding for 5 proteins i.e. 
glycoprotein (G), large protein (L), phosphoprotein (P), matrix protein (M) and 
nucleoprotein N. Its genome is associated with N, L and P proteins to form the 
nucleocapsid. Together the L and P proteins form the RNA dependent RNA 
polymerase that is involved in the transcription of the genome [104]. The M 
protein is involved in the later steps of viral replication and condenses the 
nucleocapsid to a tightly coiled structure. The outer membrane of virion is the 
envelope composed of a cellular lipid bilayer. The transmembrane G protein is 
anchored in the viral envelope, which is essential for receptor binding and cell 
entry [105] 
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Figure 1: Genome organisation and packaging of VSV (adapted from 
http://viralzone.expasy.org/) 
Negative-stranded RNA linear genome; about 11 kb in size. Encodes for 5 proteins. Enveloped, 
bullet shaped, 180 nm long and 75 nm wide. 
 
Like nearly all viruses, VSV can also evade type I IFN action [106,107]. The M 
protein plays a major role in the virus-induced inhibition of host gene 
expression. It has been proposed that the inhibition of host gene expression by 
M protein is responsible for suppressing activation of host IFN gene expression. 
Most wild-type strains of VSV induce little if any interferon gene expression, 
while mutant viruses such as AV2 which have a mutation in the M protein can 
mount a normal IFN response [106,107]. WT VSV 
M protein suppresses interferon gene expression by inhibiting host RNA and 
protein synthesis. 
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3 AIM OF THIS WORK 
 
VSV is a cytopathic virus, belonging to the family Rhabdoviridae, capable of 
causing encephalitis in mice. Type I IFN is rapidly induced upon infection and is 
crucial to prevent death [108]. In fibroblast cells, type I IFN production and 
action is efficiently blocked by the virus [109]. Previous results demonstrate that 
IRF-1 mediated an antiviral response in the absence of type I IFN induction by 
direct transcriptional activation of ISGs [42,86]. 
In this study we aimed to uncover the role of IRF-1 mediated antiviral responses 
by IFN independent mechanisms in vivo. Since VSV is a neurotropic virus, we 
questioned if IRF-1 had a particular role of executing antiviral innate responses 
in the CNS. Our efforts were aimed to uncover the mechanisms by which 
neurotropic viral infections are cleared by IRF-1 dependent mechanisms. We 
also aimed to uncover the cell types in the brain which execute these 
responses. Moreover the extents to which the IRF-1 mediated antiviral 
responses are essential to the host were also investigated.  
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4 RESULTS 
 
In the past years, many studies have demonstrated the role of the IRFs in 
coordinating innate immune signalling events downstream of PRR signalling 
and regulating the IFN response. However, certain factors such as IRF-1 have 
been shown to mediate antiviral responses by inducing ISGs by IFN 
independent mechanisms as well. VSV is a neurotropic virus of the 
Rhabdoviridae family that efficiently blocks type I IFN induction and function in 
vitro. Thus by using the model of VSV infections in vivo, we aim to uncover the 
separate roles of IRF and IFN in antiviral defences.  
4.1 IRFs play a crucial role to defend against VSV infections 
To investigate the role of various IRFs in mediating antiviral responses in vivo, 
we used gene knockout mice to study their increased susceptibility to VSV. WT 
mice infected intranasally (i.n.) with 107 plaque forming units (pfu) of VSV 
displayed a mere 20% mortality (Figure 2). In contrast, IRF-3-/- and IRF-7-/- mice 
were found to be susceptible to i.n. VSV infections with sublethal doses of 106 
pfu, displaying 100% mortality. IRF-5-/- mice are also previously shown to be 
susceptible to VSV infections [62]. IRF-1-/- mice were also found to be 
susceptible to VSV infections, displaying 100% mortality and were dead within 7 
days after showing sign of encephalitis. These data show that many of the IRF 
family members play a crucial role in antiviral defences against VSV. To also 
study the importance of the type I IFN response in antiviral defences, type I IFN 
receptor knockout i.e. IFNAR-/- mice were also used in the study. As these mice 
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are previously reported to be very susceptible to many virus infections, they 
were infected i.n. with a low dose of 102 pfu of VSV. Despite the administration 
of low VSV doses, all IFNAR-/- mice died very early i.e. within 3 days. These 
data confirm that type I IFN plays a crucial role in the early and immediate 
responses against VSV infection.  Importantly, we conclude that IRFs are also 
pivotal for survival of VSV infection, albeit at higher infectious doses and at 
slightly later time points of the infection.  
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Figure 2: IRFs protects mice from lethal intranasal VSV infection 
Survival analysis of WT (n=12), IFNAR
-/-
 (n=5), IRF-1
-/-
 (n=10), IRF-3
-/-
 (n=10) and IRF-7
-/-
 
(n=10)   mice, infected i.n. with VSV at doses as indicated in the figure. Data are representative 
of at least two independent experiments. Survival differences were tested for statistical 
significance by the log-rank test. 
4.2 IRF-1 has a special antiviral action in the brain upon VSV infection 
We previously demonstrated that IRF-1 mediates a type I IFN independent 
antiviral response against VSV in vitro [42], which proves to be essential when 
viruses evade innate immune responses by antagonizing the induction and 
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function of the type I IFN system. Upon intranasal infection VSV enters the CNS 
by directly infecting the olfactory receptor neurons [92]. Since VSV is a 
neurotropic virus, we wanted to analyse if the IRF-1 mediated antiviral action 
was necessary to combat neuropathogenesis in vivo. Therefore to investigate if 
IRF-1 plays a specific role in neurotropic VSV infection we compared systemic 
and CNS infection by infecting them via different routes i.e. i.n. for a neurotropic 
infection and i.v. for a systemic infection.  IRF-1-/- mice were found to be 
susceptible to i.n. VSV infection at sub lethal doses (Figure 2). In contrast, 
systemic VSV infection of IRF-1-/- mice showed no increased susceptibility in 
comparison to WT mice (Figure 3A). IFNAR-/- mice were very susceptible to 
systemic VSV infections and died within 3 days. Interestingly, intranasal 
infection of mice infected with the non-neurotropic Influenza PR-38 virus had 
little impact on the survival of IRF-1-/- mice, as most of them survived the 
infection, similar to the infected WT mice (Figure 3B). These data indicate that 
while type I IFN responses are essential to protect from both neurotropic and 
systemic VSV infections, IRF-1 mediated antiviral responses are crucial only for 
neurotropic VSV infections. 
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Figure 3:  IRF-1 has a specific antiviral action in the brain.  
A, Survival curves of WT (n=5) , IRF-1-/- (n=6) and IFNAR-/- (n=5) mice after i.v. 
infection with 5 x 106 pfu VSV. B, Survival curves of WT and IRF-1-/- mice after 
intranasal infection with 0.04 MLD50 Influenza A virus PR8/A/34. 
Data are representative of at least two independent experiments. Survival 
differences were tested for statistical significance by the log-rank test. 
4.3 IRF-1 is not a regulator of type I IFN or type III IFN 
VSV replication is reported to be controlled by type I IFN [108,110]. Previous 
studies with other viruses have implied IRF-1 as an activator of IFN-α/β gene 
transcription in cell culture [111].Therefore, we determined the impact of IRF-1 
on the IFN response upon VSV infection. To this end, we determined IFN-α 
serum levels in VSV infected mice (Figure 4). Equal levels of IFN-α were 
detectable in the serum of both WT and IRF-1-/- mice at 6 hours and 24 hours 
post infection. However, IRF-1-/- mice displayed higher IFN-α in the serum 2 
days post infection. No IFN-α was detectable in WT and IRF-1-/- mice from day 4 
post infection. 
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Figure 4: IRF-1 is not a regulator of IFN-α. 
 Mice were infected i.n. with 5 x 10
6
 pfu of VSV. Serum was collected from WT and IRF-1
-/-
 mice 
6, 24, 48, 96 and 144 hours post infection. IFN-α protein was detected by ELISA. Data 
represents mean with SEM of 5-6 mice in each group per time point. Asterisks indicate statistical 
significance calculated by Mann-Whitney test, ** p<0.005. 
 
 
To determine the impact of IRF-1 in IFN-β production, we took advantage of an 
IFN-β+/Δβ-luc reporter mouse [112], which allows tracking of IFN-β gene induction 
in vivo. Intranasal VSV infection of IFN-β+/Δβ-luc, IRF-1+/-IFN-β+/Δβ-luc, IRF-1-/-IFN-
β+/Δβ-luc showed no differences of reporter gene expression within them (Figure 
5). The signal reached its maximum, 48 hours post infection after which it 
declined. Since the IFN- β levels are not differentially regulated between WT 
and IRF-1-/-mice we conclude that IRF-1 is not a regulator of IFN-β.  
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We could previously demonstrate that IRF-1-/- mice had no deficiency in their 
type I IFN activity in comparison to WT mice (Figure 4/5). To further investigate 
with IRF-1 had any impact on the induction of type III IFNe also took advantage 
of a MX2Luc reporter mouse which allows whole body in vivo imaging of type I 
and III response using firefly luciferase as a reporter [113]. Both type I and type 
III IFNs can specifically induce the MX2 gene and since the MX genes in inbred 
mouse strains are not functionally translated and, the disruption or manipulation 
of these genes should not signiﬁcantly alter cellular functions [114,115]. Since, 
the type I IFN levels are not altered between WT and IRF-1-/- mice, any 
difference in luciferase expression detected would be contributed by the type III 
IFN. Intranasal VSV infection of IRF-1+/-MX2luc induced reporter gene 
expression in the whole body, with a major response in the region of the liver 24 
+/+ +/- +/+ +/- -/- +/+ +/- -/- +/+ -/- +/+ +/- -/- +/- -/- IRF-1 
0 24 48 96 72 
hours post infection 
Figure 5: IRF-1
-/-
 mice have no defects in induction of IFN- β 
IFN-β
+/Δβ-luc
, IRF-1
+/-
 IFN-β
+/Δβ-luc
, IRF-1
-/-
 IFN-β
+/Δβ-luc
 transgenic mice were i.n. infected with 
5x10
6
 pfu of VSV and subjected to whole body imaging. Mice were imaged before treatment 
(0h) and over time as indicated. Images from a representative mouse are shown. The rainbow 
scale indicates the number of photons measured per second per cm
2
 per steradian (sr). 
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hours post infection (Figure 6A). The signal reached its maximum, 48 hours 
post infection after which it declined. No differences of luciferase signals was 
detectable in IRF-1+/+Mx2Luc mice (data not shown), IRF-1+/-MX2luc and IRF-1-
/- MX2luc mice. Detailed analysis of luciferase expression in different organs 
revealed a slightly higher type I IFN response in some organs of IRF-1-/- mice 
compared to WT controls (Figure 6B). In WT mice the IFN responses in the 
brains were back to basal levels by day 9 post infection. These results 
confirmed that a lesion in the IRF-1 gene does not lead to diminished levels of 
Type I IFN. This corroborates the evidence that there is no deficiency in IFN 
action and is not responsible for the increased susceptibility of IRF-1-/- mice.  
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4.4 Both IRF-1 and type I IFN responses are crucial for antiviral 
responses against VSV in the CNS 
Since VSV is a neurotropic virus, we investigated the impact of IFN and IRF-1 
dependent antiviral responses in the CNS. To this end we made use of 
conditional IFNARfl/flNesCre+/- mice that suffer from the IFNAR deletion 
specifically in neuroectodermal cells of the CNS such as neurons and astrocytes 
Figure 6: Systemic type I IFN response cannot rescue IRF-1
-/-
 mice from VSV infections. 
 
 
 
IRF-1
+/-
MX2luc and IRF-1
-/-
MX2luc transgenic mice were infected i.n. with 5x10
6
 pfu of VSV. 
A. Mice were subjected to whole body imaging. Mice were imaged before treatment (0h) and 
over time as indicated. Images from a representative mouse are shown. The rainbow scale 
indicates the number of photons measured per second per cm
2
 per steradian (sr).B, 
Luciferase activity from the homogenized organs of uninfected or infected IRF-1
+/-
MX2luc and 
IRF-1
-/-
MX2luc transgenic mice were quantitated at indicated days post infection (d.p.i).  
Data represents mean with SEM of 4-8 mice in each group per time point.  
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but not microglia [116]. A previous study reported that i.n VSV infection of 
IFNARfl/flNesCre+/- led to their death in 6 days [108].  Infection of these mice with 
a dose of 5x106 pfu of VSV, IFNARfl/flNesCre+/- succumbed to the infection by 6 
days post infection after dramatic experiencing weight loss (Figure 7). With this 
we conclude that type I IFNs are a potent antiviral defence mechanism against 
neurotropic VSV infections.  
To investigate if IRF-1 can also execute antiviral actions in the CNS 
independent of the type I IFN signalling, IRF-1-/-IFNARfl/flNesCre+/- were infected 
with the same dose of VSV and their survival kinetics were followed. IRF-1 
deficient IRF-1-/-IFNARfl/flNesCre+/- mice succumbed to the infection within day 2 
and 5 post infection which was earlier than the fate of IFNARfl/flNesCre+/- mice 
(Figure 7). This indicates that apart from the IFN system, IRF-1 is able to 
execute additional antiviral functions in the brain. Together, these data suggest 
a pivotal antiviral function of both IRF-1 and type I IFN in the brain. The data 
also suggest both IFN and IRF-1 can execute their activities independent of one 
another.   
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Figure 7: The action of IRF-1 is independent of the type I IFN  
Mice were infected intranasally with 5 x 10
6
 pfu of VSV. Survival analysis of IRF-1 sufficient 
(IRF-1
-/-
) (n=3) or deficient (IRF-1
-/-
) (n=5) IFNAR
fl/fl
NesCre
+/-
 mice.  
Statistical significance was calculated by the log-rank test. 
 
4.5 IRF-1 mediated antiviral response is independent of the B cell 
responses. 
Earlier work has demonstrated the importance of adaptive immune system for 
survival during VSV infection. In particular, a depressed neutralizing antibody 
response in the periphery promotes early dissemination of the virus to the CNS 
[37]. To assess if the severe phenotype of IRF-1-/- mice post VSV infection was 
due to an ill antibody response, we evaluated whether IRF-1 modulates the 
humoral immune response by determining VSV neutralizing antibodies (Figure 
8). Similar levels of VSV specific IgM and IgG titres were detected in IRF-1-/- and 
WT mice. These data suggest that the increased viremia in the CNS of the IRF-
1-/- is not due to a defect in the B cell response.  
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Figure 8: The antiviral effects of IRF-1 are not driven by the B cell response 
WT and IRF-1
-/-
 mice were infected intranasally with 5 x 10
6
 pfu VSV and serum samples were 
collected at the indicated time points. Virus specific IgM and IgG titres were quantitated by the 
virus neutralization assay. 
4.6 IRF-1 mediated antiviral responses are independent of T cell 
mediated responses 
Previous studies have demonstrated that T cells are required for the long term 
survival of VSV infection. IRF-1 transcriptionally regulates the expression of 
certain MHC class I molecules such as LMP-2, TAP-1. As a result MHC class I 
cell surface expression is decreased in IRF-1-/- mice [43,47].  Moreover, IRF-1-/- 
mice fail to mount a normal Th1 response upon a pathogen challenge because 
IRF-1 transcriptionally regulates the p40 subunit of IL-12 [46,117]. As a result, 
naïve IRF-1-/- mice display defects in the frequency of CD8+ T cells in peripheral 
organs such as the spleen (Figure 9A). The defects are also consistent when 
the total CD8+ T cells are quantitated in cell numbers from the spleen (Figure 
9B). Although the frequency of CD4+ T cells in the spleen seem higher in the 
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IRF-1-/- mice, no differences in CD4 cell numbers were found between the WT 
and IRF-1-/- mice (data not shown).  
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Figure 9: IRF-1
-/-
 mice have lower numbers of CD8+ T cells 
A, Representative ﬂow cytometry proﬁles of spleen CD3
+
CD8
+
 T cell staining from uninfected 
WT and IRF-1
-/- 
mice are shown. B, Total numbers of CD8
+
T cells in the spleen of WT and IRF-
1
-/- 
are shown.  
Asterisks indicate statistical significance calculated by Mann-Whitney test, ** p<0.005. 
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Since i.n. infection of VSV leads to viral replication in the brain [108], infiltration 
of T cells in the brain as a part of the host immune response were expected. We 
compared the levels of CD8+ T cells infiltrating the brains of IRF-1-/- and WT 
mice. Significantly lesser frequencies as well as numbers of CD8+ T cells 
infiltrated the brain of IRF-1-/- mice (Figure 10A/B). The lesser numbers of 
infiltrating CD8+ T cells is likely due to the lesser numbers of CD8+ T cells in 
these mice.  
 
 
 
 
 
 
 
                      
                  
 
A 
C
D
3
 F
IT
C
 
CD8 APC-Cy7 
WT IRF-1
-/-
 
RESULTS 
27 
 
BRAIN
0
2
4
6
8
10
0 6
** WT
IRF-1-/-
days post infection
C
D
8
+
T
c
e
ll
s
 (
x
1
0
4
)
 
Figure 10: Infected IRF-1
-/-
 mice have lesser numbers of CD8
+
 T cells infiltrating the brain 
Mice were infected i.n with 5x10
6 
pfu of VSV.A, Representative ﬂow cytometry proﬁles of brain 
infiltrating CD3+CD8
+
 T cells from 6 days post infected WT and IRF-1
-/- 
mice are shown.B, Total 
numbers for CD8
+
 T cells in the brains of uninfected and 6 days post infected WT and IRF-1
-/-
 
mice were evaluated. 
Asterisks indicate statistical significance calculated by Mann-Whitney test, ** p<0.005. 
 
T cells are known to play a role in the long term survival after VSV infection. To 
investigate the impact of the lower T cell number in IRF-1-/- mice we adoptively 
transferred WT T cells into IRF-1-/- mice. T cells were isolated from the spleens 
of WT mice expressing a congenic marker Thy1.1 and then transferred into both 
WT and IRF-1-/- mice. 2 days post transfer the number of WT Thy 1.1 cells were 
analysed in the IRF-1-/- mice (Figure 11 A) and then subsequently infected.    
IRF-1-/- mice that were supplemented with T cells did not show any improvement 
in their survival rate post i.n. VSV infection and still died in 6 days (Figure 11B).  
Therefore we conclude that in this model of VSV infection, T cell response have 
no impact in IRF-1 mediated antiviral response. 
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Figure 11: The anti-viral effects of IRF-1 are not driven by CD8
+
 T cells. 
A, Representative flow cytometry profiles of Thy 1.1-CD3
+
 WT T cells in spleens of IRF-1
-/-
 mice 
2 days post transfer. B, Survival analysis of WT (n=5) and IRF-1
-/-
 (n=4) mice adoptively 
transferred with 10
7
 T (Thy1.1) cells, 2 days prior to intranasal infection with 5x10
6 
pfu VSV. 
Survival differences were tested for statistical significance by the log-rank test. 
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4.7 IRF-1 mediated antiviral responses are mediated by the brain resident 
cells 
While the systemic IFN response and neutralizing antibodies have no impact on 
the IRF-1 mediated antiviral responses, we asked if the antiviral action of IRF-1 
is due to stromal and brain resident cells or the hematopoietic system facilitates 
an indirect control of VSV infection. Since the hematopoietic cells are sensitive 
to irradiation while the brain resident cells are resistant [40], we established 
reciprocal bone marrow chimeric mice by lethal irradiation of CD45.1 WT or 
CD45.2 IRF-1-/- mice, followed by adoptive transfer. After 6-8 weeks, we tested 
the mice for chimerisms and found that the donor cells had replenished the 
bone marrow (Table 6) and then subsequently infected i.n. with VSV. WT → WT 
chimeras were a little bit more susceptible than WT mice but 70% were capable 
of limiting infection. IRF-1-/- → WT showed comparable susceptibility to VSV 
infection like WT → WT mice, while WT → IRF-1-/- chimeras were unable to 
rescue the IRF-1-/- mice (Figure 12A). This suggests that loss of IRF-1 
expression in haematopoietic cells has no impact on survival of the mice while 
IRF-1 expression in host stromal and resident brain cells is critical to control the 
virus. 
To investigate if WT → IRF-1-/- chimeras are more susceptible due to 
differences in the recruitment of lymphocytes compared to the WT → WT 
chimeras, we analysed brain infiltrating T cells in the chimeric mice. The data  
revealed no differences in the number of donor CD8+ T cells between WT → 
WT and  WT → IRF-1-/- chimeras (Figure 12 B/C). Moreover, CD8+ T cells in 
the brains of IRF-1-/- or WT recipients were neither activated nor antigen specific 
(data not shown). Thus, the IRF-1 mediated antiviral effects are driven primarily 
by radiation-resistant stromal or brain resident cells.  
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Figure 12: The anti-viral effects of IRF-1 are neither driven by the adaptive immune 
responses nor by the hematopoietic cells. 
WT and IRF-1
-/-
 mice were lethally irradiated and reconstituted with bone marrow from IRF-1
-/-
 or 
WT mice. Mice were tested for their chimerism after 6-8 weeks and i.n. infected with 5 x 10
6
 pfu.  
A, Survival was monitored and plotted as Kaplan-Meier curves (n=8-10). Data are 
representative of two independent experiments. Survival differences were tested for statistical 
significance by the log-rank test, * p<0.05. B, C Leukocytes were isolated from brains of 
chimeric mice (n=6-9) 6 days post infection, stained for CD45.1 and CD8, and analysed by ﬂow 
cytometry, B, Representative ﬂow cytometry proﬁles of WT CD8
+ 
T cells from donor 
hematopoietic cells in the recipient irradiated WT and IRF-1
-/-
 mice. C, Total cell numbers for 
infiltrating donor WT CD8+ T cells in the brains of WT and IRF-1
-/-
 mice. 
 
 
4.8 The antiviral effects of IRF-1 are dispensable for clearance in the 
peripheral organs 
Intranasal administration of a high viral dose of VSV leads to viral replication in 
the brain as well as in peripheral organs where it first reaches the lung and then 
disseminates to the other tissues [108]. We therefore determined viral load from 
various peripheral tissues by plaque assay 2, 4, 6 days post intranasal infection 
with 5 x 106 pfu of VSV (Figure 13). VSV titres were quantitated as plaque 
forming units per gram (pfu/g) from the peripheral organs. Viral titres were 
higher in the. liver, spleen and lungs of IRF-1-/- mice in comparison to WT mice 
C 
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(248.8, 466.5 and 5,64 fold higher respectively ), 2 days post infection. 
However, viral clearance from the liver and spleen of both WT and IRF-1-/- mice 
was observed by day 4. Higher VSV titres were found in the lung than the other 
tissues but were cleared by day 6 post infection. These data indicate that IRF-1 
had an impact in limiting viral replication but clearance of the virus from 
peripheral organs could be achieved even in the absence of IRF-1. 
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Figure 13: IRF-1 mediated antiviral effects are dispensable in the peripheral organs. 
WT and IRF-1
-/-
 mice were infected i.n. with 5 x 10
6 
pfu of VSV. Viral burden was quantitated by plaque assay from peripheral organs- liver, 
spleen and lung. Data are representative of at least two independent experiments.  
Asterisks indicate statistical significance calculated by Mann-Whitney test, * p<0.05. 
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4.9 Dynamics of viral replication in the brain of w.t. and IRF-1-/- mice  
Intranasal administration of VSV leads to spread from the nasal cavity to the 
olfactory bulb and into the CNS [92,118]. To examine the impact of IRF-1 in 
brain infection in more detail, we determined the viral load in different brain 
parts, i.e olfactory bulb, cerebrum, cerebellum and brain stem (Figure 14). At 2 
days post infection, viral titres of WT mice  were highest in the olfactory bulb 
(2.087x106pfu/g) compared to the cerebrum (1.22x105 pfu/g), cerebellum 
(1.34x105 pfu/g) and the brain stem (1.15x105 pfu/g), 2 days post infection. WT 
mice cleared the virus within 6 days. At 2 days post infection IRF-1-/- mice had 
similar titres to WT mice which declined by 4. However by day 6, only the 
olfactory bulb could clear the virus with similar kinetics compared to the 
peripheral tissues and a surge of viral load was found in the brain tissues of 
IRF-1-/- mice. High viral titres developed at this time point in the cerebrum, 
cerebellum and brain stem, suggesting this as a cause for the death of these 
animals. These data indicate that IRF-1 plays a negligible role during the early 
phase of viral brain infection and clearance. However, IRF-1 is crucial in the 
control of a second phase of viral replication in the cerebrum, cerebellum and 
brain-stem.  
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Figure 14: IRF-1 controls viral replication in the brain. 
WT and IRF-1
-/-
 mice were infected intranasally with 5 x 10
6 
pfu of VSV. Viral burden was 
quantitated by plaque assay from brain parts- olfactory bulb, cerebrum, cerebellum and brain 
stem. Data are representative of at least two independent experiments. 
Asterisks indicate statistical significance calculated by Mann-Whitney test, * p<0.05. 
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4.10 IRF-1 prevents spread of the virus 
To support the contention that IRF 1 mediates protection specifically in the brain 
and the increased CNS virus titers in the absence of IRF-1 are due to more 
effective spread, we perform immunohistological analysis on infected brains of 
WT and IRF-1-/- mice at early and late time points. To track the differences of 
viral spread within the brain regions of WT and IRF-1-/- mice. We used a GFP 
labelled reporter virus (VSV-eGFP) (Figure 15A/B). At early time points, 2 days 
post infection; no differences in the patterns of viral spread were visible between 
the WT and the IRF-1-/- mice (Figure 15A). In the olfactory bulb which is the first 
target site for VSV, VSV-eGFP signals were detected exclusively within the 
glomeruli of both WT and IRF-1-/- mice. Within the regions of the cerebrum, only 
the striatum was found to be infected in the WT and the IRF-1-/- mice. Other 
regions of the cerebrum such as the internal capsule and hippocampus in IRF-1-
/- mice showed no infection at this time point. 
At day 6 post infection, high VSV-eGFP signals were detectable in the regions 
of the brain stem, striatum, internal capsule and hippocampus of IRF-1-/- mice. 
In contrast, no virus was detectable in brains of infected WT mice at this time 
point (Figure 15B). This data indicates that in the absence of IRF-1, VSV is able 
to spread to different regions within the cerebrum and other parts of the brain. 
Interestingly, high VSV-eGFP was detectable in neuron axonal fibers of the 
internal capsule. This data indicates that IRF-1 helps control viral spread to 
other vital brain regions which are important for the survival of the mice. In 
addition IRF-1 plays a minor role during the early phase of viral brain infection 
and clearance. However, IRF-1 is crucial in the control of a second phase of 
viral replication and spread in the cerebellum, cerebrum and brain-stem. 
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Figure 15: IRF-1 prevents viral spread in the brain. 
WT and IRF-1
-/- 
mice were infected with 5x10
6 
pfu of VSVeGFP. Immunohistological analysis of VSV-eGFP in the olfactory bulb, brain stem and 
different parts of the cerebrum (striatum, internal capsule and hippocampus) at A, 2 days post infection and B, 6 days post infections,  merge: 
VSV-eGFP (green), DAPI (blue). Scale bar is 100 µm 
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4.11 IRF-1 mediates an antiviral activity that inhibits a secondary wave of 
virus propagation that cannot be controlled by the action of IFN-β 
To dissect the different roles of type I IFN and IRF-1 during VSV infection in the 
brain, we determined IFN-β mRNA expression in different brain parts after i.n. 
infection with VSV by quantitative RT-PCR (Figure 16). Interestingly, the IFN-β 
mRNA expression pattern and kinetics differed within the various brain regions. 
In the olfactory bulb IFN-β expression were detectable 2 days post infection, 
and its expression level declined to basal levels by day 4. No difference in IFN-β 
mRNA expression level was detectable between WT and IRF-1-/- mice. These 
data correlate to the kinetics of viral load where IRF-1 has no impact in the 
control of viral replication in the olfactory bulb. 
In the cerebrum and cerebellum of IRF-1-/- mice, a resurgence of IFN-β mRNA 
induction was observed at day 6 post infection, which correlated to higher viral 
replication in the absence of IRF-1. The kinetics of IFN-β expression levels 
within the cerebrum and cerebellum indicated little if any IFN-β mRNA was 
produced at day 2 post infection. However, significant amounts of IFN-β were 
found only in the cerebrum and cerebellum of IRF-1-/- mice, 6 days post 
infection. These data indicate that loss of IRF-1 leads to higher viral replication 
in the late phase of virus infection, although IFN-β is expressed and 
corresponds well to the kinetic of enhanced viral replication in IRF-1-/- mice in 
the late phase. Thus, in both brain parts, cerebellum and cerebrum, loss of IRF-
1 leads to higher viral replication in the later phase of infection in the presence 
of IFN-β, indicating its non-redundant function of type I IFN and IRF-1 in 
mediating antiviral activity.  
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Figure 16: Type I IFN response in the IRF-1
-/-
 mice is not compromised. 
WT and IRF-1
-/-
 mice were infected i.n. with 5 x 10
6
 pfu of VSV.  Expression level of IFN-β mRNA in different brain parts i.e. A, olfactory 
bulb, B, cerebrum and C, cerebellum was determined by real-time RT-PCR. 
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4.12 ISG responses are not influenced by the loss of IRF-1 
IRF-1 directly induces antiviral IFN stimulated genes independent of type I IFN 
[42]. To define the antiviral status of the brain we investigated the induction of 
several prominent interferon stimulated genes (ISGs) within the cerebrum where 
high viral replication was observed (Figure 17A/B/C/D). Increased RNA 
expression levels of the ISGs Mx2, Rsad2, and USP-18 mRNA were found in 
both WT and IRF-1-/- 2 days post infection, followed by a decline. However, 
expression levels increased again on day 6 post infection in IRF-1-/- mice, which 
correlates to IFN-β induction. IFIT-2 mRNA, which has been previously defined 
as an ISG to restrict VSV replication in the brain [118], was induced only at day 
6 post infection. Interestingly, an increase of ISG expression in the cerebrum 
was also detectable in WT mice in the absence of detectable amounts of IFN-β 
mRNA. From this we suggest, that induction of these tested ISGs in the 
absence of IFN-β could be IRF-1 dependent.  
Immunohistological analysis showed that IFIT-2 is expressed in brains of both, 
WT and IRF-1-/- mice, although VSV infection is not detectable in WT mice 
(Figure 17E). IFIT-2 expression is only detectable in non-infected cells of WT 
animals. In contrast, in IRF-1-/- mice VSV positive and negative cells expressed 
IFIT-2. Collectively, these data suggest two waves of antiviral response in the 
brain after i.n. VSV infection. While the first wave of antiviral responses peaking 
at day 2 is IFN-dependent and induces long lasting ISG expression, the second 
wave is IRF-1 dependent and limits viral replication and spread.
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Figure 17: Type I IFN response in the IRF-1
-/-
 mice are not compromised. 
Mice were infected intranasally with 5 x 10
6
 pfu of VSV. A/B/C/D, mRNA expression level of 
ISGs MX2, Rsad2, USP-18 and IFIT-2 from cerebrum was determined by real-time RT-PCR. 
Data represents mean with SEM of 3-7 mice in each group per time point. Asterisks indicate 
statistical significance calculated by Mann-Whitney test, ** p<0.005, * p<0.05.E, 
Immunohistological analysis of VSV-eGFP and IFIT-2 protein 6 days post infection in the 
cerebrum of IRF-1
-/-
 mice. IFIT2 (red), DAPI (blue), VSV-eGFP (green). Scale bar is 50µm. 
 
4.13 Brain specific induction of IRF-1 
To confirm our hypothesis we determined IRF-1 expression in peripheral organs 
and the different brain parts of WT mice during the course of infection (Figure 
18). Although high viral replication was found in the lung at early time points, 
IRF-1 mRNA expression was not detectable in the lungs at any time point post 
infection, suggesting that it does not play a role in this tissue. In contrast, IRF-1 
mRNA was expressed in all the regions of the brain, albeit with different kinetics. 
In the olfactory bulb, IRF-1 mRNA was induced strongly 2 days post infection 
and remained abundant until day 6. In the cerebrum, IRF-1 was induced only 6 
days post infection, whereas in the cerebellum, IRF-1 was induced 2 days post 
infection, declined on day 4 and then remained induced until day 6. These data 
showed that induction of IRF-1 was tissue and time point specific and could be 
crucial for survival against VSV induced neuropathogenesis. 
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Figure 18: IRF-1 is induced at later states during VSV infection in the brain 
WT mice were infected i.n. with 5 x 10
6
 pfu of VSV. Expression level of IRF-1 in A, lung and 
B/C/D, in different brain parts were determined by real-time RT-PCR.  
Asterisks indicate statistical significance calculated by Mann-Whitney test, ** p<0.005. 
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4.14 IRF-1 is induced by type I IFN independent mechanisms 
IRF-1 has previously been described to be capable of being induced 
independent of type I IFN [42,86]. To investigate if IRF-1 induction mechanism 
was mediated by the type I IFNs in the brain, we used IFNARfl/flNesCre+/- mice 
which lack IFNAR signalling in neuroectodermal cells. We made use of this 
system because IFNAR-/- mice die within 2 days (Figure 1) and hence the time 
points post infection was not long enough the IRF-1 mediated antiviral response 
which usually comes 5-6 days post infection. The IFNARfl/flNesCre+/- mice on the 
other hand survives long enough to investigate the second wave of antiviral 
response (Figure 7). A strong induction of IRF-1 mRNA was detectable within 
different brain parts upon intranasal VSV infection (Figure 19). Thus we 
conclude that IRF-1 is induced in the brain by type I IFN independent 
mechanisms.  
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Figure 19: IRF-1 is induced by type I IFN independent mechanism. 
IFNAR
fl/fl
NesCre
+/-
 mice was infected i.n. with 5 x 10
6
 pfu of VSV.  Data represents fold induction 
of IRF-1 in the brains parts at 6 days post infection calculated over expression levels of IRF-1 in 
uninfected mice.  
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4.15 IRF-1 is induced by type III IFN independent mechanisms 
The type III IFN signals through a receptor distinct from that of type I IFN but 
triggers the same signal transduction pathway downstream of the receptor and 
induces antiviral response[119]. To check if IL-28 also known as IFN-λ is 
induced in the brain after VSV infection, we measured the presence of IL-28 and 
its receptor IL28R in the cerebrums of both WT and IRF-1-/- mice by quantitative 
RT-PCR. Consistent with previous reports that states that IL-28 is very poorly 
expressed in the CNS in response to a variety of virus[120], expression of IL-28 
as well as the IL-28 receptor were below detection limits (Figure 20A/B). In 
contrast, lung samples from 4 day post infected mice were used as positive 
controls for IL-28 and IL-28R detection and showed high expression levels. 
Thus, our data suggest that IRF-1 and ISG expression in the brain can be 
induced independent of type III IFN- and that both the type I IFN and the IRF-1 
mediated antiviral effects are essential to restrict VSV induced 
neuropathogenesis. 
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Figure 20: IRF-1 is induced by type I and Type III IFN independent mechanism. 
WT and IRF-1
-/-
 mice were infected i.n. with 5 x 10
6
 pfu of VSV. mRNA expression of A, IL28 
and B, IL28R from the cerebrum of WT and IRF-1
-/-
 mice. Positive controls (+) included lung 
samples of VSV infected WT mice from day 4 post infection.  
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4.16 i.n. VSV infection leads to strong production of IFN-γ in the CNS of  
IRF-1-/- mice but not in WT mice 
IRF-1 is known to be strongly induced by IFN-γ by the activation of STAT1 
[121]. Thus we investigated if the induction of IRF-1 in the brain resident cells 
was mediated by IFN-γ secreted by the lymphocytes.  We first determined the 
kinetic of IFN-γ mRNA expression levels in the brains of infected WT and IRF-1-
/- mice (Figure 21 A/B/C). In the olfactory bulb, no IFN-γ mRNA was induced in 
both WT and IRF-1-/- mice. In the cerebrum and cerebellum little or no IFN-γ 
mRNA was induced at any time point in the WT mice. In contrast to WT mice, 
IRF-1-/- mice induced very large amounts of IFN-γ 6 days post infection. This 
data supports the previously reported hypothesis that IRF-1-/- CD8+ T cells 
undergo a rapid expansion of antigen specific T cells compared to their WT 
counterparts. Therefore, although the CNS of IRF-1-/- have lower numbers of 
CD8+ T cells, the antigen specificity of these cells are higher than those of their 
WT counterparts.  This explains why higher levels of IFN-γ are found in the 
CNS.  
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Figure 21: High levels of IFN-γ can be detected in the brains of IRF-1 mice. 
A/B/C, WT and IRF-1
-/-
 mice were infected i.n. with 5 x 10
6
 pfu of VSV. mRNA expression of IFN-γ were quantitated from different brain parts 
i.e. A, olfactory bulb, B, cerebrum and C, cerebellum. Asterisks indicate statistical significance calculated by Mann-Whitney test, ** p<0.005, 
* p<0.05 
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4.17 IRF-1 is induced by type II IFN independent mechanisms 
Since we detected a marginal but non-significant increase of the type II IFN i.e. 
IFN-γ, we investigated if the induction of IRF-1 in the brain resident cells was 
contributed by IFN-γ producing cells. IFN-γ expression in the CNS has been 
known to be attributed by infiltrating NK cells and antigen specific T cells. Since 
no NK cells were found infiltrating the brains of infected both WT and IRF-1-/- 
mice, we excluded the possibility of NK cells being mediators of IRF-1 induction 
the brain (Figure 22A). Although T cells were found to be infiltrating the infected 
brains of WT mice, we argued that these cells were not antigen specific 
because IFN-γ was very poorly induced in the brain post infection (Figure 21). 
To further corroborate our hypothesis that IRF-1 is induced by type II IFN 
independent mechanisms in the brain, Rag2-/- mice, which lack T cells were 
infected i.n. with VSV. All the regions of the brain tested i.e. the olfactory bulb, 
cerebrum and the cerebellum showed IRF-1 mRNA induction 6 days post 
infection albeit to different levels (Figure 22B). Hence we conclude that the type 
II IFN producing cells types that are in usually thought to play a role in CNS 
infection do not play a role in the induction of IRF-1 in the brain resident cells 
during i.n. VSV infections.  
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Figure 22: IRF-1 is induced by typed II IFN independent mechanism in the brain 
A, WT and IRF-1
-/-
 mice were infected i.n. with 5 x 10
6
 pfu of VSV. Leukocytes isolated from 
brains of WT and IRF-1
-/- 
6 days post infection by Percoll gradient centrifugation, stained for 
CD8
+
 T cells (CD3
+
CD8
+
) and NK cells (DX5
+
CD3
-
) were evaluated. Asterisks indicate statistical 
significance calculated by Mann-Whitney test, ** p<0.005. B, Rag
-/-
 mice was infected with 5x10
6 
pfu of VSV. mRNA expression of IRF-1 in Rag2
-/-
. Data represents fold induction of IRF-1in the 
brains parts at 6 days post infection calculated over expression levels of IRF-1 in uninfected 
mice.  
 
4.18 IRF-1 dependent antiviral mechanisms are driven by innate immune 
mechanisms in neurons 
The primary target for VSV replication in the brain has been reported to be the 
neurons [108,118]. To assess if the source of the antiviral responses were 
governed by innate immune mechanisms, we monitored the viral replication 
kinetics in primary hippocampal cultures prepared from WT and IRF-1-/- mice 
(Figure 21). Immunofluorescence analysis revealed that VSV could infect only 
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the neurons of these cultures (Figure 21A). In addition, determination of viral 
titres in the cultures revealed a two-fold higher viral titre in IRF-1-/- cells 
compared to WT cells (Figure 21B). This data shows that neurons possessed 
an inherent IRF-1 dependent antiviral mechanism to defend against VSV 
infection. 
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Figure 23: IRF-1
-/- 
neurons are more susceptible to VSV than WT neurons 
A/B Primary hippocampal neurons were cultured from WT and IRF-1
-/-
 mice. A, WT neurons 
were infected with 0,01 MOI VSV-eGFP. 24 hours post infection; cultures were stained with 
GFAP (astrocytes) and NeuN (neurons) by immunofluorescence assay. B, WT and IRF-1
-/-
 
neurons were infected with 0.001 MOI VSV and viral replication from 24-48 hours were 
measured by plaque assay.  
Asterisks indicate statistical significance calculated by Mann-Whitney test, ** p<0.005. 
GFAP NeuN VSV merge 
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4.19 Loss of IRF-1 does not change the tropism of the virus 
Viral infection experiments showed that IRF-1 limit viral replication specifically in 
neurons in vitro. To address whether the increased CNS virus titers in the 
absence of IRF1 in vivo are just due to more efficient viral spread in the brain or 
also due to a change in cell tropism we performed immunohistological analysis 
of 6 days post infected IRF-1-/- brains. The data revealed an effective infection of 
VSV-eGFP in neurons, whereas most of the astrocytes and all microglia remain 
uninfected. Interestingly, some of the microglia was associated with infected 
cells (Figure 12). This confirmed that neurons possess an inherent IRF-1 
dependent antiviral mechanism to defend against VSV infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
54 
 
 
 
 
Figure 24: IRF-1
-/-
 mice were infected i.n. with 5 x 10
6
 pfu VSV.  
Immunohistological analysis of VSV-eGFP (green) in neurons (NeuN: red), astrocytes (GFAP: red) of the cerebrum and microglia (IBA: red) from 
the brain stem 6 days post infection. 
Scale bar is 50µm 
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4.20  IRF-1 mediates antiviral responses in the brain 
The CNS is typically regarded as an immune privilege site because peripheral 
immune cells are generally blocked by the blood brain barrier (BBB). However, 
neuroinflammation can be initiated in response to a pathogenic attack. 
Inflammation is associated with the breakdown of the BBB and attraction of 
several inflammatory cells to the target site. Since, infected IRF-1-/- mice have 
enhanced viral replication in their brain and succumb with symptoms of fatal 
encephalitis, we characterised the extent of the inflammatory response in WT 
and IRF-1-/- mice post i.n. VSV infection (Figure 25A/B). Higher numbers of 
infiltrating monocytes characterised by CD45Hi CD11b+ expression level were 
quantitated in the knockout mice compared to their WT counterparts 6 days post 
infection. At this time point higher numbers of activated microglia characterised 
by the CD45LoCD11b+ expression levels were also detectable the IRF-1-/- mice. 
These results suggested that IRF-1-/- mice had more severe inflammatory 
responses in the brain.  
One of the characteristics of neuroinflammation is the secretion of 
proinflammatory cytokines by the immune cells in the brain. To support the 
hypothesis that IRF-1-/- mice experience a more severe inflammatory response 
than their WT counterparts, we measured mRNA levels of proinflammatory 
cytokines IL-1ß and TNF-α from the cerebrum (Figure 25C/D). The mRNA 
expression of both cytokines was increased in the IRF-1-/- cerebral tissues. 
These data suggest that higher replication of VSV by the loss IRF-1 leads to 
enhanced inflammatory response which could contribute to encephalitis leading 
up to neurotoxicity and death.   
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Figure 25: The absence of IRF-1 leads to an inflammatory response in the brain 
WT and IRF-1
-/-
 mice were infected intranasally with 5 x 10
6
 pfu VSV. A/B, Leukocytes were 
isolated from brains of WT and IRF-1
-/- 
6 days post infection by Percoll gradient centrifugation, 
stained for CD11b and CD45, and analyzed by ﬂow cytometry, A, Representative ﬂow cytometry 
proﬁles of CD11b and CD45 staining of brain leukocytes from WT and IRF-1
-/- 
mice are shown, 
B, Total cell numbers for infiltrating monocytes (mono) (CD45Hi CD11b+), microglia (mg) 
(CD45Lo CD11b+) CD8
+
 T cells (CD8
+
) and NK cells (DX5
+
CD3
-
) were evaluated. C/D, 
Expression levels of IL-1ß and TNF-α mRNA were recorded by real-time RT-PCR from the 
cerebrum of WT and IRF-1
-/-
 mice.  
Asterisks indicate statistical significance calculated by Mann- Whitney test, ** p<0.005, * p<0.05. 
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5 DISCUSSION 
 
The central nervous system (CNS) harbours highly differentiated cells, such as 
neurons that are essential to coordinate the functions of complex organisms. 
Numerous cell types act in accord to maintain its integrity and its functions, 
separated into three main groups: neurons, the glia, and endothelial cells. This 
organ is partly protected by the blood-brain barrier (BBB) from toxic substances 
and pathogens carried in the bloodstream. For decades, the immune privilege of 
the CNS was understood as an absence of an immune system inside the CNS, 
and the BBB was considered only as a barrier isolating the CNS from the 
peripheral immune system, preventing the entry of infectious agents and 
immune cells into the CNS [96]. Extensive work in the last decade unravelled 
the presence of a specialised intrinsic innate immune system in the CNS. 
5.1 Role of IRF-1 in antiviral responses in the CNS 
The innate immune system is essential to limit viral replication before adaptive 
immunity is stimulated. The engagement of viral PAMPs on TLRs and RLRs are 
known to drive IFN-β mediated antiviral responses while NLRs are known to 
drive antiviral responses mediated by IL-1β. Both type I IFN and IL-1β mediated 
responses have shown to play important innate responses in the CNS against 
neurotropic viruses. In this study, using VSV as a model for neurotropic 
infections we report IRF-1 as an essential regulator of host innate antiviral 
response that is not involved in rapid IFN induction.  
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The susceptibility of IRF-1-/- mice to VSV depends on the route of infection. 
While IRF-1-/- mice succumb to i.n. VSV infection at a sub-lethal dose, all mice 
survive the infection by the i.v. route. This could be due to the fact that this 
transcription factor plays a non-redundant role in certain cell types. Upon 
intranasal infection, VSV infects olfactory receptor neurons and is transported to 
the olfactory bulb via the olfactory nerves, from where the virus spreads trans-
synaptically to other regions of the brain [92]. However, upon i.v. VSV infection, 
virus replication is restricted to the periphery. Unlike other members of the IRF 
family such as IRF-3 and IRF-7, IRF-1 does not need to undergo post-
translational modifications to become active. IRF-1 instead needs to be induced 
to carry out its antiviral activities. Our results show that i.n. VSV leads to IRF-1 
induction in the CNS but not in the periphery. Hence, IRF-1 is a crucial 
transcription factor driving antiviral activities in special cells of the CNS.  
 
5.2 Antiviral action of IRF-1 against VSV 
Although IRF-1 was originally identified as an IFN inducer upon virus infection 
[36,122,123], the antiviral effect of IRF-1 was not due to a hampered type I IFN 
response. Instead, other members of the IRF-family such as IRF-3 and IRF-7 
have been identified as regulators for type I IFN expression [54,66]. 
Mechanistically, IRF-1 and type I IFN are known to induce partially overlapping 
sets of ISGs that show broad antiviral activity against a range of viruses, but 
several studies have shown specific genes to be mediated directly by IRF-1 
[87,124]. Detailed analysis of the viral titres from different brain regions revealed 
a temporal role of IRF-1 in the control of viral replication. While type I IFN plays 
a critical role in early stages of infection, IRF-1 is essential in limiting viral 
replication at later stages. Our data also suggests that while the IFN mediated 
antiviral effects might be driven by the olfactory bulb, IRF-1 mediated antiviral 
are redundant in the olfactory bulb at any time point. Instead, other regions of 
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the brain i.e. the cerebrum, cerebellum and the brain stem are dependent on the 
IRF-1 mediated antiviral mechanisms to defend against the virus at the late 
stages of infection.  Moreover, analysis of viral titres as well as the kinetics of 
IFN-β in the different brain parts suggested an IFN-independent antiviral 
response by IRF-1.  
Previous in-vitro studies identified that IRF-1 could induce antiviral mechanisms 
in the absence of type I IFN signalling. To confirm if such a mechanism could 
exist in the CNS, infection experiments with IRF-1-/- NesCre+/-IFNARfl/fl and IRF-
1+/- NesCre+/-IFNARfl/fl mice were carried out. The former succumbed earlier to 
the infection, indicating essential antiviral responses by IRF-1 that are 
overlooked due to the strong effects of type I IFN. IFIT-2 is identified as an ISG 
that plays a significant role against VSV in the brain. However, IFIT-2 is induced 
in the brain of IRF-1-/- mice with kinetics exactly similar to IFN-β, indicating that 
the effect of IRF-1 could be through a distinct group of IRF-1 regulated genes. 
One study demonstrated the IRF-1 mediates induction of an otherwise known 
ISG gbp-2 in the absence of type I IFN [125]. This demonstrates the possibility 
of distinct subgroups of ISGs which co-ordinate IFN dependent and independent 
effector functions. 
5.3 Neurons hold intrinsic innate immune defences 
Literature has previously described microglia as crucial immune cells of the 
brain. However, more recent studies have shown neurons capable of executing 
crucial antiviral defence mechanisms. IFNAR-/- neurons as well as IL-1β r-/- 
neurons show increased susceptibility to viral infection than their WT 
counterparts [108,126]. VSV infection in the brain leads the virus to selectively 
replicate in neurons [118]. We showed that the loss of IRF-1 did not change the 
tropism of the virus and primary hippocampal neurons isolated from IRF-1-/- 
mice showed higher VSV replication rates compared to WT control. Recently it 
was reported that neurons from evolutionary distinct regions of the brain 
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respond differently to WNV infection [127]. No impact of IRF-1 was detectable in 
the olfactory bulb, while all other brain regions tested showed an IRF-1 
dependent decrease of viral load. This observation is also in line with VSV 
infection studies in primary olfactory neurons, which show no impact in IRF-1 
mediated antiviral response induced by IFN-γ [128]. In the absence of IRF-1, 
VSV can more effectively spread to different regions of the brain such as the 
brain stem, the striatum, the internal capsule and the hippocampus which are 
crucial regions of the brain. The infection of the internal capsule, which 
separates caudate nucleus and the thalamus from the patatum and globus 
pallidus could explain how VSV is able to overcome natural barriers in the brain 
and infect additional regions in the brain. 
Our findings indicate that the increase of viral load is not due to a broader 
cellular tropism and neurons are still the primary target for VSV replication and 
spread. However, other uninfected cell types in the vicinity of infected cells 
might still be involved in executing antiviral effects. Virus infection of astrocytes 
and microglia was reported in in vitro cultures and intranasal infection of young 
mice [129]. Infection of 3-4 week old mice with very high doses VSV does not 
reflect the same infection model as ours, because the BBB is not fully 
developed in mice less than 6 weeks old. However, our results indicate that the 
microglia is activated post i.n. VSV infection as expression of proinflammatory 
cytokines could be quantitated. Microglia is very commonly referred to as the 
“resident macrophage like cell-type” in the CNS. IRF-1-/- macrophages are more 
susceptible to VSV replication than their WT counterparts suggesting that IRF-1 
has an innate role in this cell type (unpublished data).Moreover production of 
inducible nitric oxide synthase (iNOS) which is a potent compound against a 
variety of pathogens, is induced by IRF-1[41]. Hence, it is worth investigating if 
IRF-1 plays a role in microglia responses against VSV although these effects 
could be indirect as microglia were not found infected but some showed them 
touching infected neurons. Similarly the role of IRF-1 in astrocyte mediated 
responses is also worth investigating.  
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5.4 Role of adaptive immunity in i.n. VSV infections 
Previous studies have reported the essential role of the adaptive immune 
response against VSV infections. Besides innate resistance mechanisms, 
neutralizing antibodies also control VSV replication in peripheral organs and 
inhibit lethal viremic spread of VSV to the CNS [130]. It has been demonstrated 
that IRF-1-/- mice display several defects in adaptive immune response, 
therefore an impaired response could have contributed to death of VSV-infected 
IRF-1-/- mice. We found normal VSV-neutralizing antibody response in the 
serum of IRF-1-/- mice. Although T cell responses are not crucial for VSV 
infections as T cell deficient mice or mice with T cell depletion showed no 
impact on VSV replication [131], virus-specific T cells can be found at late time 
points. IRF-1-/- mice have a blunted and dysfunctional CD8+ T cell response. 
However, in WNV infection CD8
+
 T cells were fully capable of lysing target cells 
and clearing viral infection from neurons and the brain [132]. In VSV infected 
brains, lower numbers of CD8+ T cells are detected. In bone marrow chimeric 
mice reconstituted with WT donor cells, IRF-1-/- and WT recipients showed a 
competent T cells infiltration in the infected brains. Despite this IRF-1-/- 
recipients showed no signs of improved survival. In addition, IFN-γ mRNA 
expression is low. Moreover, Rag2-/- mice could also induce IRF-1 in the 
different brain regions. Thus we conclude that the IRF-1 signalling in the brain 
resident cells is critically required to restrict virus replication.  
IRF-1-/- mice have a defective Th1 T cell response because IRF-1 plays a role in 
the transcription of IL-12 and IL-12R. However, since we could establish that in 
the context of i.n. VSV infection, T cell responses play a minor role, it makes it 
an excellent model for studying innate immune responses. However, for other 
pathogenic challenges for which the host relies on a competent T cell response 
to combat the infection, IRF-1-/- mice are susceptible [133].  IRF-1 deficient mice 
show a higher susceptibility to viral infection with different viruses such as 
EMCV, murine γ-herpesvirus 68 or West Nile virus [132,134,135]. However, the 
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antiviral response of IRF-1 is pathogen specific because as infection with  
Nippostrongylus brasiliensis can be controlled in the knockout animals [46,136]. 
 
5.5 The synergistic action of IFN and IRF-1 in the CNS 
The critical finding of this study is that the control of VSV infection in mice is 
carried out in two waves of antiviral responses (Figure 26). In the first wave, the 
host responds to virus entry, replication and spread to the different brain parts. 
This response is characterized by type I IFN induction which is crucial to limit 
viral replication in both WT and IRF-1-/- mice. Thus viral titres within the different 
brain regions drop by day 4 post infection in both the mice but however, a 
complete viral clearance is not achieved. The second wave of antiviral 
responses which is clearly IRF-1 mediated is thus required to achieve complete 
clearance. IRF-1-/- mice shows a resurgence of viral load in the cerebrum, 
cerebellum and the brain stem. The function of IRF-1 is non-redundant to type I 
IFN activity and the slightly higher concentrations of IFN-β in IRF-1-/- mice are 
possibly induced by increased viral load but still succumb to the infection. The 
strict limitation of type I IFN responses to the early phase of infection could be 
due to its potential negative effects in CNS. Type I IFNs were recently shown to 
have both beneficial and detrimental effects in the central nervous system and a 
strict regulation is necessary to co-ordinate a tightly balanced equilibrium 
between cellular activation and inhibition [137]. IRF-1 could be essential to 
maintain that homeostasis in the brain.  
5.6 Potential IRF-1 inducting mechanisms 
With the exception of embryonic cells, IRF-1 is expressed in basal levels in all 
cell types examined. For IRF-1 activity to be executed, IRF-1 does not have to 
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be post-translationally be modified like IRF-3 and IRF-7 to become active. IRF-1 
intrinsically activates gene expression with levels of expression determining its 
activity. Therefore, to have antiviral activity IRF-1 first needs to be induced. Both 
type I and type II IFN can induce IRF-1 but our data suggests that during i.n. 
VSV infections the second wave of IRF-1 mediated antiviral action is driven by 
an IFN independent mechanism. Insights to how and what induces IRF-1 in 
neurons is yet to be discovered.  
IL-1β responses mediated by the inflammasome signalling have also been 
identified as crucial innate immune responses against neurotropic viruses such 
as WNV [138]. IL-1β is a known inducer of IRF-1 but this could be cell type 
specific [139,140]. If the inflammasome signalling Is involved in the induction of 
IRF-1 in the brain resident cells is also yet to be investigated.  
Other possibilities for IRF-1 induction in neurons could be either direct PRR 
signalling events such as the involvement of MyD88 or MAVS signalling in the 
induction of IRF-1 or by proinflammatory cytokines such as TNF-α and IL-1. 
Both possibilities are equally valid as two independent studies show antiviral 
signalling pathway which leads to MyD88 and IRF-1 interaction following TLR 
activation [141,142]. Moreover, IL-1 and TNF are already known to be an 
inducer of IRF-1 [140].  
Signalling events leading to STAT-1 phosphorylation have previously been 
identified as the mechanism for IFN independent IRF-1 induction in fibroblasts 
[42]. Therefore, it is possible that any PRR signalling event that could lead to 
STAT-1 activation is a potential IRF-1 inducing mechanism. 
Which mechanism plays a role in inducing IRF-1 in the CNS in response to 
pathogenic challenges still remains un-investigated.  
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Figure 26: Model describing two waves of antiviral responses regulating defences 
against i.n. VSV infection.  
 
 
 
5.7 Evolutionary perspective into IRF-1 mediated antiviral defenses 
In contrast to type I IFN, IRFs are not secreted from cells indicating that an IRF-
mediated antiviral response is cell intrinsic and therefore limited to infected cells. 
This leads us to believe that IRF mediated antiviral defence is the ancient 
response while the IFN mediated action has evolved to strengthen the innate 
immune network.  
With time more viruses are finding ways to circumvent the IFN action. Therefore 
in future, cells would have to rely on other non-redundant antiviral mechanism to 
defend itself from viral attack. Hence, there is an urgent need to identify other 
non-redundant mechanisms for antiviral defences. Given that the IRF family is 
crucial for host defence immunity against pathogens, a more detailed 
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understanding of how the IRF system’s signalling pathways are turned on and 
off could make the IRF family an attractive target for therapy for infectious 
diseases. 
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6 MATERIALS AND METHODS 
6.1 Consumables 
Table 3: List of consumables used 
Article Company 
Cell culture plates (96 well, 24 well, 12 well) Nunc, Corning 
Tissue Culture dishes Corning, Greiner Bio-one 
Tissue culture flasks (25cm
2
, 75cm
2
, 125cm
2
) Corning, Greiner Bio-one 
Flow cytometry tubes Sarstedt 
Combi tips Eppendorf 
Safe lock tubes Eppendorf 
PCR tubes Kisker Biotech, Steinfurt 
Cryovials Corning 
Reaction tubes (15ml and 50 ml) Greiner Bio-one 
Probe tubes 2ml Omnilab 
Cell strainer (40µm and 70µm) BD Falcon 
 
 
Table 4: List of equipment used 
Equipment Product Name and Manufacturer Model 
Autoclave Belimed Dampf Sterilisator 6-6-6 HS1,FD 
Cell Counter Casy-DT 1, Schaerfe Systems - 
Cell separator MACS Miltenyi  
Centrifuges 
Eppendorf 
 
Heraeus Biofuge 
 
Hettich Rontana/S 
 
Cooling Centrifuges Sorvall 
 
Superspeed 
 
Minifuge Heraeus-Christ 
 
5417C 
 
13 
 
- 
 
 
- 
RC5 
 
- 
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Heraeus Biofuge fresco 
 
Inflexible rotors 
 
Swing rotor 
 
Juan 
- 
 
GSA, GS3, SS34 
 
HB4 
 
CR412 
Deionized water Milli-Q  
Eliza Reader 
Multiskan EX reader, Thermo  
 
Electron Corporation 
- 
Fast Prep MP  
Freezer 
-20°C:Liebherr 
- 80°C: Thermo Forma 
GS3183? 
Fridge Liebherr UKS3600 
Incubators for Cell Culture Labotect C200 
In Vivo, Bioluminescence Imaging 
Machine 
 
Xenogen IVIS system, Caliper 
 
IVIS 200 
Light Cycler Roche 480 
LSM LSM Carl Zeiss Confocal - 
LSR II BD  
Luminometer Berthold Lumat LB 9507 
Microwave Whirlpool Pro 825 
Mini centrifuge 
Heraeus Christ Minifuge GL 
 
Biofuge fresco 
- 
- 
Micropipettes Gilson - 
Nitrogen tank HarscoK-Series 17K 
PCR Machine T3 Thermocycler, Biometra - 
pH meter Beckmann M340 
Photometer Nanodrop ND-1000 
Pipettor Pipetboy IBS Integra Biosciences - 
Power Pack Biorad Power Pac 1000 
Precision Weighing Scale Sartorius - 
Sterile Work Benches 
Steril Gard Class II Type A/B3, Baker 
Company. 
 
Herasafe, Heraeus 
SG 400E 
 
 
HSP 18 
Thermomixer Eppendorf 5436, 6350 
pH meter Beckman M340 
Vortex Scientific Industries Vortex Genie 2 - 
Water Bath GFL - 
 
MATERIALS AND METHODS  
69 
 
6.2 Chemicals 
The chemicals used were supplied by the following companies: Amersham 
Biosciences, Bayer, Biolabs, Bioline, BioRad, BRL Difco, Gibco, Merck, 
Promega, Qiagen, R&D systems, Roche, Seromed, Serva and Sigma.   
Enzymes were  purchased  from  Bioline,  Invitrogen, Promega, Roche and 
oligonucleotides were synthesized at Eurofins MWG Operon.  
Antibodies were purchased from eBioscience, SYSY, Sigma, Millipore and 
Beckton Dickenson.  
6.3 Consumables 
Materials for working with eukaryotic cells were purchased from companies 
Corning, Gibco, Sigma, Nunc. 
6.4 Computer software 
This  thesis  was  written  using  the  Microsoft  (MS)  Word  97-2003  version.    
Tables, calculations  and graphs  were  constructed  on  MS  Excel  97-2003  as  
well  as Graph pad PRISM.  Figure design and annotation was performed with 
MS PowerPoint 2010   Microscopical image analysis was performed with 
ImageJ (National Institutes  of  Health) .Flow  cytometry  data  was  acquired  
with LSRII (BD) and  analyzed using FlowJo v7.6 . Quantitative PCR (qRT-PCR)  
results were analyzed and calculated using the LightCycler 480 software. 
Preparation of figures and statistical analysis of data was done using GraphPad 
Prism. 
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6.5 Sterilisation 
Glassware  was  sterilized  at  180˚C  for  4  hours  prior  to  use.  Plastic 
materials such as Eppendorf tubes, pipette tips and solutions for cell culture 
were autoclaved at 121˚C for 25 minutes. Solutions that could not be autoclaved 
were filtered through a 0.22μm filter under a clean working bench.   
6.6 Photometric determination of nucleic acids 
Concentration  of  nucleic  acids  was  assessed  by  measuring  absorbance  at  
A260  on  a Nanodrop-1000. Purity of nucleic acids preparation was determined 
by the A260/280 ratio. A  value  appreciably  lower  than  1.8  and  2  for  DNA  
and  RNA  respectively  indicates contamination due to protein, phenol or 
organic compounds in the sample. 
6.7 Virus 
In this study, vesicular stomatitis virus (VSV) of serotype Indiana (Mudd-
Summers isolate) was used. Virus production was carried out on BHK cells. 
6.8 Cell culture 
 Cell culture work was carried out in a sterile workbench with vertical air flow. 
The working surface and the equipment used before and after working was 
disinfected with 70% ethanol.  In addition, disposable consumables or 
autoclaved or sterile-filtered solutions or media were used. Before starting work, 
all solutions and media were on preheated in a 37°C water bath. Vero cells and 
primary neuronal cells were cultured at 37°C with 5% CO2 and 95% relative 
humidity.  
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6.8.1 DMEM (Dulbecco's Modified Media)  
13,63 g/l DMEM Puder (Sigma), 3,67 g/l (44 mM) Sodium Hydregen carbonate 
2,6 g/l, 10 mM HEPES, pH 7,2 
 
6.8.2 100 x Pen / Strep 
6.06 mg / ml ampicillin (10,000U/ml), 10 mg/l streptomycin, pH 7.4, stored at -
20°C 
 
6.8.3 100 x Glutamine 
29.23 mg/ml glutamine, sterile filtered, stored at -20 ° C 
 
6.8.4 Media for Vero cells 
DMEM, 1 × Pen/Strep, 1 x glutamine, 10% FCS (Lonza) 
 
6.8.5 Media for Neuronal cells 
Neurobasal media (Invitrogen) supplemented with 2% B27 (Invitrogen), 2x N-2 
supplement (Invitrogen), 1% Pen/Strep and 0.5 mM Glutamax.  
 
6.8.6 Phosphate buffer saline (PBS) 
140 mM NaCl, 27 mM KCl, 7.2 mM Na2HPO4, 14.7mm KH2PO4, pH 6.8-7.0 
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6.8.7 Gey's balanced salt solution (GBSS) 
0,22 g CaCl2·2H2O, 0.370 g  KCl, 0.030 g KH2PO4, 0.210 g MgCl2·6H2O, 0.070 
g MgSO4·7H2O, 8000 g NaCl, 0.227 g NaHCO3, 0.120 g Na2HPO4 1000 g D-
glucose in 1000ml H2O 
 
6.8.8 GBSS/Glucose 
50ml GBSS+0.5% 50% Glucose, pH 7.2, sterile filtered. 
 
6.8.9  TEP (trypsin EDTA) 
6 mM EDTA, 0.1% trypsin (Gibco) in PBS 
 
6.8.10 Passaging cultured cells 
When cells in a flask reach 90% confluency, they should be passaged. The cells 
were first washed in PBS, trypsin with TEP for a few minutes. The reaction of 
trypsin is stopped by DMEM media which contains 10% FCS, the inactivating 
factor.  
 
6.8.11 Neuronal cell isolation and infection 
All the dissection tools should be sterilised in ethanol and then heat flamed 30 
minutes before starting the procedure. The procedure should be carried out on 
ice. Primary cultures of mouse hippocampal neurons were prepared from 
mouse embryos E18. Embryos were decapitated and the brains were kept in 
ice-cold Gey's balanced salt solution supplemented with glucose (refer 6.8.7 
and 6.8.8). After dissection the hippocampi were isolated and then dissociated 
by 30 min incubation with trypsin followed by mechanical separation using a 
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Pasteur pipette. 70.000 Cells were seeded on poly-L-lysine coated cover slips 
and incubated in Neurobasal medium (Invitrogen) supplemented with 2% B27 
(Invitrogen), 2 x N-2 supplement (Invitrogen) and 0.5 mM Glutamax at 37°C, 5% 
CO2 and 99% humidity. After 3 weeks, cells were infected with either VSV or 
VSV-eGFP (MOI-0.001). Kinetics of viral replication was recorded by plaque 
assay. 
6.9 Animal experiments 
6.9.1 Ethics statement 
All animal experiments were performed according to the guidelines of the 
German Animal Welfare Law (AZ 33.9-42502-05-12A295 and AZ 33.14.42502-
04-070/08). The approved animal code is 070/08 and 11/0528. 
All preparative work was carried out under semi-sterile conditions and to avoid 
contamination with exogenous pathogens, all devices were thoroughly cleaned, 
disinfected with 70% ethanol and autoclaved. 
 
6.9.2 Animal housing 
Transgenic mice are bred and maintained in the tier 1 facility of the Helmholtz 
Centre for Infection research (HZI) under SPF conditions.C57BL/6 or WT mice 
were bought from Harlan Laboratories. The genotypes of all mice were verified 
by PCR.  
Before infection, mice are transferred to the tier 2 facility (S2). In both facilities at 
the HZI, mice are maintained in standard ventilated cages standard (IVC system 
Green Line, Tecniplast Germany GmbH) in same-sex groups. Standard 
conditions for housing of animals include twelve-hour light-dark cycle, air 
exchanges of 15 times per hour, illuminance of 50 lux, temperature of 22 ° C, 
55% humidity, water and food pellets.  
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Table 5: List of Mice used in this study 
Genotype Background Reference 
C57BL/6 C57BL/6 Harlan Laboratories 
Thy1.1 C57BL/6 [143] 
CD45.1 C57BL/6 [144] 
IRF-1
-/-
 C57BL/6 [145] 
IFNAR
-/-
 C57BL/6 [146] 
IRF-3
-/-
 C57BL/6 [54] 
IRF-7
-/-
 C57BL/6 [147] 
IFN-β
+/ Δβ-luc
 C57BL/6 [112] 
MX2luc C57BL/6 [113] 
IFNAR
fl/fl
CreERT C57BL/6 [108] 
IFNAR
fl/fl
NesCre
+/-
 C57BL/6 [108] 
  
6.9.3 Blood isolation and serum collection 
Blood could be drawn by two different methods; cardiac puncture and isolation 
from the retroorbital vein. For the former, mice were killed with CO2, their chest 
was cut open and a syringe with a 0.55X25mm needle was used to draw blood 
from the heart. To draw blood from a living mouse, mouse was firmly ficked by 
the neck and the retrobulbar venous plexus which is a vein that lies in the corner 
of the eye was punctured with a glass capillary. Then by applying the right 
amount of pressure the glass capillary was twisted in till blood flowed out into 
the capillary.  
To obtain the serum, blood was incubated for 2 hours at RT or overnight at 4 ° C 
to ensure blood coagulation. To separate the serum from the coagulated blood, 
samples were centrifuged at 2000g for 20 min. The top clear phase was the 
serum which was then isolated.  
6.9.4 Adoptive transfer 
 After purifying pan T (CD4+ and CD8+ T cells) cells isolated from a congenic 
mouse by magnetic separation (refer 6.20), 1 × 107 cells were injected i.v into 
each mouse in 100µl PBS. 48 hours post transfer, success of transfer was 
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analysed by tracing back the injected cells by flow cytometry (refer 6.19). Mice 
were subsequently infected with VSV (refer 6.9.7).  
6.9.5 Bone marrow chimeras 
Bone marrow chimeras were generated with modifications to the previously 
described protocol [148]. 
6-8 week old WT and IRF-1-/- mice were irradiated with a lethal dose of 950 rad. 
The next day bone marrow were isolated from the tibia and femur of 4-6 week 
old IRF-1-/- or WT (CD45.1) mice and were injected i.v. with 1 x107 bone marrow 
cells in 100µl PBS into the irradiated mice. Mice were kept on antibiotics 
(Baytril) for 2 weeks. Six-eight weeks after bone marrow transplantation, WT 
(CD45.1)WT (CD45.2), IRF-1-/- (CD45.2)WT (CD45.1), WT (CD45.1)IRF-
1-/- were bled via retro-orbital puncture (refer 6.9.3) to evaluate the efficiency of 
chimerism (table 6). The next day chimeric mice were infected i.n with VSV. 
Survival of chimeras was monitored. 
 
 
Table 6: Transplantation efficiency in the chimeric mice  
 WT → WT WT → IRF-1
-/-
 IRF-1
-/-
 → WT 
% Donor cells found in the 
blood of chimeras 
85,6 81,6 96,2 
 
 
6.9.6 Administration of anaesthesia 
For short term anaesthesia, 1-2 ml isoflurane (Albrecht) was poured on a tissue 
and placed in a container. The mouse was placed in the container, covered with 
the lid and observed until it became unconscious. Mice stay anesthetized for 30 
seconds with this procedure. 
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To administer anaesthesia for longer time periods, mice were injected 100 μl/10 
g body weight a sterile solution of 10% ketamine (WDT), 5% Rompun or Xylazin 
(CP-Pharma) in 0.9% Nacl. This procedure allows mice to stay unconscious for 
approximately 30 min.  
6.9.7 Virus infection 
For intranasal infection (i.n), mice were anesthetized with ketamine / Rompun or 
xylazine solution and thus placed under general anesthesia (refer 6.9.6). All 
virus infections were carried out with 5X106 pfu of VSV/VSV-eGFP and 0.04 
MLD50 of Influenza A virus PR8/A/34unless stated otherwise. Virus was mixed 
with PBS to a total volume of 20µl and administred carefully into both nostrils.  
For intravenous infection (i.v.), virus suspended in 100µl of PBS was 
administered into the tail vein of the mouse.  
6.10 Virus quantification from tissues 
Virus titers from tissues were carried out as previously described with minor 
modifications [108]. In brief, VSV infected mice were euthanized and blood was 
removed from organs by cardiac perfusion with 25 ml of PBS. Organs were 
isolated and were snap-frozen in liquid nitrogen. On the day of the experiment, 
organs were thawed, weighed; homogenized using Fast Prep 24 (MP) in 1.5 ml 
of PBS. The homogenised organ mixture was centrifuged at 2000g for 30 min 
and 200µl of the supernatant was used to quantify the total amount of virus in 
10-fold serial dilutions on Vero cells by plaque assay. Results are expressed as 
plaque-forming units (pfu) per gram of tissue.  
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6.11 IFN-α ELISA 
The amount of murine IFN-s in mouse serum was determined by enzyme-
linked immunosorbent assay (ELISA) according to the manufacturer's 
instructions (eBioscience). 
6.12 In vivo imaging 
For in vivo imaging, mice were injected intravenously with 150 mg/kg of D-
luciferin in PBS (CaliperLS), anesthetized using Isoflurane (Baxter) and 
monitored using an IVIS 200 imaging system (CaliperLS). Photon flux was 
quantified using the Living Image 3.2 software (CaliperLS). 
6.13 Determination of viral titres/ Plaque assay 
For the detection and quantitation of infectious viral particles, plaque assay was 
performed. Since VSV is a cytopathic virus, the virus creates a pattern of holes 
on a uniform cell layer due to infecting neighbouring cells. These holes are 
referred to as plaques. To quantitate VSV from organs tissues, they are first 
homogenized in 1.5 ml of 1% BSA using FastPrep-24 (MP). The sample is 
centrifuged at 2000g for 30 min. A fraction of the supernatant is collected and 
added to a confluent layer of VERO cells in a series of 10-fold dilutions and 
incubated for 2 hours at 37°C. 
To quantitate virus from the supernatant of virus infected cells, a fraction of the 
supernatant is collected and added to a confluent layer of VERO cells in a 
series of 10-fold dilutions and incubated for 60 min 37°C.  
After the incubation of VERO cells with the virus culture, the supernatant was 
removed and the cells were overlaid with 1:1 mixture of 2 x DMEM with 10% 
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FCS / 2% ( w / v) methyl cellulose (high viscosity) to prevent free movement of 
the virus in the culture medium. After 2 days, cells were stained with crystal 
violet (1% crystal violet, 3.6% formaldehyde, 1% methanol, 20% ethanol) and 
the virus titre was determined by counting the number of plaques. 
6.14 Virus Neutralisation Assay 
The virus neutralization assay is a variant of plaque assay (refer 6.13) where 
virus specific antibodies can be detected and quantified. The assay works on 
the principle that virus specific antibodies from the serum bind to the virus and 
thus neutralize the entry of the virus into the cell. The distinction between IgM 
and IgG antibodies can be done by the addition of 2-mercaptoethanol which 
disrupts the IgM structure. This allows the measurement of only VSV specific 
IgG antibodies. The protocol for quantification of VSV specific IgM and IgG 
responses were done as described previously [149].  
Serum was diluted 1/40 and incubated with or without 2-mercaptoethanol for 1 
hour. Treated or non-treated sera were pre-diluted 1:40; heat inactivated at 
56°C for 30 min, diluted 40 fold and then diluted 1:2 with 500 pfu/ml VSV. The 
serum-VSV mixture was incubated for 90 min at 37°C and then transferred onto 
VERO cells in a series of 2 fold dilutions. After 60 minutes at 37°C, the 
supernatant was taken off and medium containing 1 % methyl cellulose was 
added to the cells. Total plaques were counted after the cells were stained with 
crystal violet. The dilution at which the serum reduced the plaque number by 
half was noted as the neutralisation titre. 
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6.15 Isolating RNA from tissues 
While working with RNA, it is necessary that we use RNAse free materials to 
prevent its degradation. TRIzol works by maintaining RNA integrity during tissue 
homogenization, while at the same time disrupting and breaking down cells and 
cell components. Homogenised samples in TRIzol were added with chloroform 
in a ratio of 1:5 and after the centrifugation, separate the solution into aqueous 
and organic phases. RNA remains only in the aqueous phase. After transferring 
the aqueous phase, RNA can be recovered by precipitation with isopropyl 
alcohol. But the DNA and proteins can recover by sequential separation after 
the removal of aqueous phase. Precipitation with ethanol requires DNA from the 
interphase, and an additional precipitation with isopropyl alcohol requires 
proteins from the organic phase. Total RNA extracted by TRIzol Reagent is free 
from the contamination of protein and DNA. RNA extraction procedure were 
carried out using the manufacturer’s protocol and stored at -80°C. RNA 
concentration was determined using the NanoDrop determined. 
6.16 Quantitative real time PCR (qRT-PCR) 
Total cellular RNA was isolated as described above. RNA in a concentration of 
1-5µg was added to cDNA ready-to-go first prime tube (GE health care) in the 
presence of oligo dT (0.5μg/3μL) and incubated at 37°C for 1 hour. The 
resulting cDNA mixture was diluted 10 times and RT-PCR was carried out to 
determine induction of IFN stimulated genes relative to a house keeping gene 
Beta-actin. To carry out the q RT-PCR, QuantiTect SYBR Green PCR Kit 
(Qiagen) was used. The PCR reaction mix of 20µl included SYBR Green 
mastermix, 10pmoles forward and reverse primer and 8µl of 1:10 pre-diluted 
cDNA. As a negative control, water was used. The reaction cycle included 95°C 
for 15 seconds, 58°C for 20 seconds and 72°C for 30 seconds. 
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Table 7: List of PCR primers 
Gene orientation Sequence 
β- actin 
forward primer 5’-TGG AAT CCT GTG GCA TCC ATG AAA-3’ 
reverse primer 5’- TAA AAC GCA GCT CAG TAA CAG TCC G-3’ 
IFN-β 
forward primer 5’- CTTCTCCGTCATCTCCATAGGG-3’ 
reverse primer 5’- CACAGCCCTCTCCATCAACT 
IRF-1 
forward primer 5’- CTC ACC AGG AAC CAG AGG AA-3’ 
reverse primer 5’- TGA GTG GTG TAA CTG CTG TGG-3’ 
Mx2 
forward primer 5’- TCA CCA GAG TGC AAG TGA GG-3’ 
reverse primer 5’-CAT TCT CCC TCT GCC ACA TT-3’ 
Rsad2 
forward primer 5’- GTC CTG TTT GGT GCC TGA AT-3’ 
reverse primer 5’- GCC ACG CTT CAG AAA CAT CT-3’ 
USP-18 
forward primer 5’- AAG GAC CAG ATC ACG GAC AC-3’ 
reverse primer 5’- CAT CCT CCA GGG TTT TCA GA-3’ 
IFIT-2 
forward primer 5’- CAC CTT CGG TAT GGC AAC TT-3’ 
reverse primer 5’- GCA AGG CCT CAG AAT CAG AC-3’ 
IFN-γ 
forward primer 5’- TGG CTC TGC AGG ATT TTC ATG- 3’ 
reverse primer 5’-TCA AGT GGC ATA GAT GTG GAA GAA-3’ 
IL28R 
forward primer 5'- CCC TGT TTC CTG ACA CTC CC-3' 
reverse primer 5'- TCA GAA AAG TCC AGT GCC CG-3' 
IL-1ß 
forward primer 5’- TCA TTG TGG CTG TGG AGA AG-3’ 
reverse primer 5’- TAA TGG GAA CGT CAC ACA CC-3’) 
TNF-α 
forward primer 5’- TGG GAG TAG ACA AGG TAC AAC CC-3’ 
reverse primer 5’- CAT CTT CTC AAA ATT CGA CTG ACA A-3’) 
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6.17 Isolation of leukocytes  
Table 8: List of required reagents for isolation of leukocytes 
Reagent Constituents 
FACS Buffer PBS, 2% FCS 
ACK (Erythrocyte) lysis 
buffer 
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH7.2-7.4, sterile 
Brain digest solution PBS, 500 µg / ml collagenase, 0.1 µg / ml TLCK, 10 µg / ml DNase 
I, 10 mM Hepes 
 
6.17.1 from Spleen 
Isolated spleen cells were mashed through a 70 micron cell strainer and 
reconstituted with 2mM PBS-EDTA as a single cell solution. Erythrocytes were 
lysed with ACK-lysis buffer and washed twice with FACS buffer.  
6.17.2 from Brain 
Brain leukocytes were quantitated from a protocol previously described [150]. In 
brief, whole brains were harvested from uninfected or i.n VSV infected mice. 
Following perfusion, brains were homogenized through a 70micron cell strainer, 
digested with a collagenase solution (500 µg/ml collagenase D, 0.1 µg/ml 
trypsin inhibitor TLCK, 10 µg/ml DNase I, 10 mM HEPES in HBSS) for 1 h at 
room temperature. Cells were separated by centrifugation at 2000g for 20 
minutes on a discontinuous 70-to-30% Percoll gradient. Cells were isolated from 
the interface, subjected to ACK lysis to eliminate the presence of erythrocytes 
and washed twice with FACS buffer.  
6.18 Isolation of Bone marrow cells 
Mice were killed with CO2. Both legs including the tibia and femurs of mice were 
cut out and skinned. All muscle tissue surrounding the bone was removed and 
MATERIALS AND METHODS  
82 
 
the bones were sterilised for 30 seconds in ethanol. Hematopoietic cells were 
flushed out of a bone with PBS using a 2 ml syringe with a 0.55X0.25mm 
needle. The cells were then subjected to ACK lysis (refer 6.17) and washed 
twice with PBS.  
6.19 Flow cytometry 
To identify and quantitate individual cells in a given lymphocytic cell mixture 
isolated from spleen or brain (refer 6.17), cells were stained with appropriate 
markers and subjected to florescent activated cell sorting (FACS) analysis. 
Isolated lymphocytes were first incubated with Fc block to prevent unspecific 
binding of antibodies for 20 minutes. Antibodies with their appropriate dilutions 
were then added on the cells and kept on ice for 30 min. Samples were washed 
three times with FACS buffer and then fixed with the Cell fixation and 
Permeabilisation kit (BD) according to the manufacturer’s instructions.  
 
Table 9: List of antibodies used in this study 
Antibody Produced at Dilution  
Fc block Group of Molecular Immunology, HZI 1:500 
Anti-mouse-CD3 FITC BD Pharmingen 1:300 
Anti-mouse-CD4 APC  BD Pharminen 1:400 
anti-mouse-CD8 APCCy7 ebioscience 1:300 
Anti-mouse-CD45 PerCPCy5.5 ebioscience 1:500 
anti- mouse CD11c PECy7 ebioscience 1:200 
anti-mouse CD 45.1 APC eboscience 1:500 
Anti-mouse B220 PE eboscience 1:400 
Anti-mouse DX5 APC eboscience 1:500 
anti- mouse CD11b PE BD Pharmigen 1:1000 
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6.20 Isolation of pan T cells by MACS 
After acquiring a single cell suspension of spleenocytes (refer 6.17.1), Pan T 
cells (CD4+ and CD8+ cells) were purified by the means of negative magnetic 
selection using pan T Cell Isolation Kit (Miltenyi Biotec GmbH) and the 
autoMACS (Miltenyi Biotec GmbH) according to manufacturer’s instructions.  
6.21 Immunofluorescence 
Cultured hippocampal neuronal cells prepared on 13mm coverslips were 
infected with VSV-eGFP (MOI-0.01) (refer 6.8.10), washed one time with PBS. 
Cells were fixed with cold 4% (w/v) formaldehyde (PFA) in phosphate-buffered 
saline (PBS) for 20 min, permeabilised with 0.02% (v/v) Triton X-100 for 3 min, 
and blocked with 1% (w/v) bovine serum albumin (Applichem) and 10% Goat 
serum (Sigma) in PBS  Markers for neurons- NeuN (Millipore), astrocytes– 
GFAP (Synaptic Systems) were diluted in  blocking solution (table 10) and 
added  incubated on the fixed cultures or serum for 60 min, followed by 
secondary antibodies for 45 min. Images were acquired on LSM Carl Zeiss 
Confocal. 
6.22 Immunohistology  
Brains were removed after cardiac perfusion with PBS followed by 4% PFA and 
incubated 24 hours in 4% PFA followed by an incubation in 30% sucrose in 0.1 
M phosphate buffer for an additional 24 hours. Subsequently, the brains were 
frozen in Tissue Tek® Compound at -80°C. 30 µm sagittal slices of the whole 
brain were cut using a freezing microtome (Frigomobil, Leica, Germany). All 
staining procedures were performed free floating. Following a 1 hour blocking 
step at room temperature in PBS containing 1% BSA, 0.2% Triton and 10% goat 
serum the slices were incubated over night at 4 °C in primary antibody solution 
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consisting of 10% goat serum and 0.2% Triton in PBS. Secondary anti-mouse or 
anti-rabbit antibodies conjugated with Cy2, Cy3, or Cy5 (Jackson 
ImmunoResearch) were incubated 1:500 in PBS for 2 h at room temperature. 
 
Table 10: List of primary antibodies used for immunofluorescence and immunohistology 
Primary antibody Specificity Produced at Dilution  
Anti-GFAP Mouse monoclonal SIGMA 1:500 
Anti-GFP Mouse monoclonal Millipore 1:800 
Anti-GFP Rabbit polyclonal Millipore 1:500 
Anti-NeuN Mouse monoclonal Millipore 1:500 
Anti-IBA1 Rabbit polyclonal Synaptic Systems 1:500 
 
6.23 Statistical analysis 
The results of this work are as mean (± standard error (SEM)) specified. The 
data generated come from at least two independent experiments. Since the 
sample size are not large enough to always follow a Gaussian normal 
distribution, statistical analysis of two independent groups were calculated by 
the non-parametric Mann-Whitney-Wilcoxon test. Asterisks represent statistical 
significance between two independent groups. * p<0.05, ** p<0.005, *** 
p<0.0005.  
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